

ANNUAL REPORT 2022



Photos

Edward F. Bonnevie
Adobe Stock

Annual report 2022

CSAM Health Group AS

CSAM Health Group AS

Drammensveien 288
0283 Oslo
Norway
corporate@csamhealth.com

© **CSAM Health Group AS 2023**

Table of contents

01	About CSAM	04
02	Highlights	06
03	Letter from the CEO	08
04	Public Safety Case Study	11
05	Business Areas	17
06	Report from the Board of Directors	20
07	Financials	32
08	Financial notes	38
09	Auditors Report	100

01

About CSAM

Caring for Life - this is what inspires the people of CSAM, each and every day.

CSAM Health Group is the leading provider of specialised software for healthcare in the Nordics. From this solid foundation the company has grown to serve more than 500 customers in 27 countries. Our highly specialised software solutions are instrumental in the clinical care processes of healthcare providers and in enabling emergency responders to enhance public safety.

Through our focused mergers and acquisitions strategy, we have built a unique blend of best-in-class innovative technology and outstanding expertise. We build long-term relationships with our customers, helping them achieve their goals, and knowing that our growth is earned by consistently delivering secure, quality software services.

Our leading product portfolio includes niche solutions in public safety, connected healthcare, women and children's health, laboratory information management systems (LIMS), medical imaging, medication management, and health analytics:

Connected Healthcare

Solutions for secure information sharing and collaboration across healthcare domains.

Medical Imaging

Complete image management solution for securely capturing, storing and sharing medical images.

Women & Children's Health

Trusted solutions to safeguard pregnancy, childbirth and infancy.

Public Safety

Robust systems for managing every aspect of emergency response.

Medication Management

Decision support and medication management for safe and effective oncology treatments.

LIMS

Comprehensive support for all aspects of blood, cell and tissue management.

Health Analytics

Improving the quality, utility, and management of medical data from collection to analysis.

CSAM aims to continue its growth, both organically and through targeted mergers and acquisitions. We position for the future by investing profits in our portfolio of products and services and creating an inspiring work environment, while always operating as a responsible business within the global community.

CSAM's headquarters are in Oslo, Norway. CSAM has more than 300 dedicated specialists in ten countries across Europe, Asia, Oceania and North America, including a wholly-owned software engineering subsidiary in the Philippines.

CSAM is listed on the Oslo Stock Exchange, Euronext Growth (CSAM) and the bond is listed on Nordic ABM. For more information on CSAM, please visit www.csamhealth.com

Our Vision

Healthcare information without boundaries.

Our Mission

Enabling excellent healthcare by providing innovative niche software.

Our People

We bring empathy, enthusiasm, and expertise to everything we do.

Highlights

2022 income of 370 MNOK, growing 12% from 2021 (331 MNOK)

Recurring revenue grew by 13% in 2022 reaching 281 MNOK, representing 76% of total revenue

Full-year organic growth of 8% in local currency (4% in NOK)

EBITDA for 2022 was 2 MNOK resulting in a 1% EBITDA margin

Profit/(Loss) for the year was -132 MNOK

Reported sales outside the Nordics increased from 9% to 13% exiting 2022

Acquired the health analytics company Carmona, further strengthening CSAM's health analytics domain. Carmona offers data analytics solutions for the life sciences sector, healthcare providers and researchers.

Established decentralised business areas responsible for growth and profitability.

Initiated a group-wide cost-saving programme delivering increased profitability and cash from operations going forward, including the transition to a leaner organisational structure.

Subsequent events

At the end of 2022, after five acquisitions in the preceding 24 months, CSAM identified that there were additional synergies to be realised by streamlining the operating model for the individual Business Areas, as well as Common Service functions. In Q1-23 the company completed the implementation of a group-wide cost-saving programme. The effect of the programme is a cost-saving of 60 MNOK annually, which will improve CSAM's financial flexibility to continue its growth.

Letter from the CEO

CSAM can look back at yet another year of top-line growth, while the integration of several simultaneous M&A projects had a temporary negative impact on 2022 profitability. The combination of our weak EBITDA and the macro-economic uncertainty made 2022 a challenging year. Still, with record-high results on sales and recurring revenues in 2022, I am proud of the CSAM team and our customers who jointly have pushed through during this extraordinary time post Covid, and secured long-term value creation.

CSAM is delivering continuously-improved software solutions to an increasing number of healthcare and emergency professionals in an expanding geographic footprint. And that expansion is complementing our most important success factor, which is to serve our existing clients. The partnerships with current customers are the backbone of our business, as they provide predictable recurring revenue streams for years, sometimes decades.

As we summarise 2022, our focus on nurturing these relationships supports long-term value creation, seeing a 12% increase in revenue over 2021, and recurring revenue reaching 76% of total revenue. Also, our international efforts are paying off, as the share of revenue from outside the Nordics grew from 9% in 2021 to 13% last year.

As we entered 2022, CSAM acquired the health analytics company Carmona which provides data analytics solutions for the life sciences sector, healthcare services and researchers. CSAM had already acquired MedSciNet in 2021 and adding Carmona has further strengthened the product portfolio in this domain, which will be attractive to existing clients seeking more advanced and holistic health analytics. We are convinced that building strong verticals like Health Analytics will benefit our customer base and ensure growth over time.

Also, the first part of 2022 saw a group-wide effort to redesign our organisation to get even closer to our customers. In addition to the structural changes, we altered mandates and responsibilities to ensure focus on organic growth and profitability. This decentralised model also makes it easier to measure the quarterly growth and profitability going forward.

We are continuously in discussions with several interesting M&A targets that meet our criteria on Customers, Code and Competence. In 2022 it became evident that executives and owners of a number of these attractive companies had expectations to valuations not compliant with our IRR requirements. Backed by a healthy cash reserve, we remain ready to strike deals, but only when the fundamentals are right and only on opportunities with high likelihood of creating value for our shareholders and demonstrating increased recurring revenue and subsequent predictability for our bond holders.

When considering revenue, Q4 was our best quarter to date, with total income of NOK 98 million and 2022 was our best year to date with 370 MNOK. The organic growth was 8% in local currency, stemming from several customer relationships across different Business Areas, securing further diversification of our long-term recurring revenues.

After five acquisitions over the previous 24 months, we identified additional synergies to be realised by streamlining the operating model for the individual Business Areas, as well as notable cost reduction in our central operations. Hence, in Q4-22 we started the implementation of a group-wide cost-saving programme to restore the profitability back to our target margin. We have drastically reduced the use of external consultants, eliminated duplicated efforts, and made some hard prioritisations on where we want to excel. Unfortunately, this process also included some redundancies and we had to see good colleagues leave. The result of this programme, which was concluded in Q1-23, is a total cost reduction of approximately 60 MNOK annually. This will improve our financial flexibility which is necessary to continue our inorganic growth.

Our growth journey continues, and we look forward to welcoming new customers, as well as new businesses. And most of all, we are excited to continue to work with our existing customers. When we meet prospective customers, partners and investors, our most valuable asset is the extensive list of customers who have chosen to grow with CSAM for many, many years. We appreciate the trust they have demonstrated, and we strive to deserve it every day when we come to work.

CSAM comes out of 2022 a leaner, stronger and more customer-centric team, and we are optimistic about the year to come.



“Our focus on nurturing our customer relationships supports long-term value creation, and we see a 12% increase in revenue over 2021, and recurring revenue reaching 76% of total revenue.”

–Sverre Flatby, CEO

Public Safety Case Study - Growth Outside the Nordics

Though CSAM has its roots in the Nordics, it is a truly international organisation, with more than 500 customers across 27 countries. In 2022, sales outside the Scandinavian markets increased from 9% to 13%. CSAM's Public Safety arm drove much of this growth. It contributed 43% of CSAM's total revenue in 2022 and grew in the Spanish, UK, New Zealand and US markets.

Executing on our M&A strategy, CSAM has expanded its presence within Public Safety from being purely a Norwegian player to now leading in the Swedish market and having a foothold in other European markets, North America and Oceania. Public Safety's non-Scandinavian revenues reached 23% in 2022.

The highlighted cases below - from Spain, North America and Oceania - exemplify how we manage to successfully enter and expand in new markets through acquisitions rather than through a more greenfield approach of establishing a subsidiary in a new territory. While the revenue share from these cases is still limited for CSAM, they illustrate how CSAM can successfully drive organic growth through geographic expansion. The examples are all from recently acquired businesses.

CSAM CoordCom - recent success in a relationship spanning decades

CoordCom is a complete 112 and emergency response system that facilitates improved communication, case handling and dispatch during an emergency. The platform speeds up every aspect of the response process, can scale to meet the customer's needs, and is built on the understanding that stability, availability, and security are critical.

The Valencian Agency for Security and Response to Emergencies (AVSRE) has the responsibility for the European emergency number 112 in Valencia, an eastern region of Spain. The agency coordinates the region's emergency services and has been a CSAM

CoordCom customer for over 25 years. That period has been defined by close collaboration with the CSAM team to develop a solution that reflects the organisation's specific operational requirements.

Starting with only one agency 25 years ago, CSAM CoordCom is now utilised by 122 integrated agencies across Valencia, including police, ambulance and fire services. The system manages around 3 million incoming calls a year - more than 8,200 every day.

In 2022, Valencia 112 AVSRE extended its contract for CSAM CoordCom, expanding its size and scope. This relationship's resilience and capacity for continued growth are grounded in the CSAM team's ability to evolve the solution, deliver new features and functions, and understand the customer's changing needs.

CSAM CoordCom Innovations in Brief

Continuous Operation - Allows Valencia 112 to update their solution with zero downtime by running parallel systems, and secures availability and resilience.

ResQWebClient - A web client designed to enable smaller services and agencies, such as rural police stations, to use CSAM CoordCom in a specific way.

Operator Case Block API - Enables customers to make changes to the system's user interface, tailoring it to their specific needs.

The Valencia 112 AVSRE case also highlights how critical existing CSAM partnerships are to bringing the system to new customers. Early in 2021, CSAM signed a contract with Amper Sistemas for the delivery of a new emergency management system for Valencia Port Authority, and CSAM has recently initiated a cooperation with the Valencian Emergency Medical Services (EMS). Both organisations had previously interfaced with the system via Valencia 112 and subsequently expressed a desire to work with CSAM to develop their own CSAM CoordCom capacity. While Valencia Port Authority has invested in its own system for port management, EMS is working with CSAM to integrate an innovative AI medical case management component into the solution.

CSAM Optima Predict - Developing a strong global presence

It was also a promising and successful year for the CSAM Optima Predict solution. Optima Predict is advanced emergency response modelling software that gives CSAM customers the ability to play out 'what-if?' scenarios, base their contingency planning on discrete event simulation models and make informed decisions about resource allocation and dimensioning. In an environment where customers need to maximise the value of scarce resources and expensive assets, these products are a highly attractive proposition.

The Optima team delivered several wins in 2022, with positive outcomes in New Zealand, the UK and North America. The Welsh Ambulance Service NHS Trust in the UK, Alberta Health Services in Canada, and the Denver Health and Hospital Authority in the US all extended their CSAM Optima contracts in 2022.

North America - building on existing partnerships and creating new ones

In 2022, Alberta Health Services and Denver Health Paramedics both extended and expanded their contracts for CSAM Optima Predict. Alberta Health Services has been particularly proactive with the solution, integrating it into their decision-making process and making the most of its versatile modelling capabilities to manage planning across an expansive area and a complex mix of rural and urban environments.

In addition, MedStar, the Texas-based pioneering EMS provider, adopted the solution. Regarded as an industry leader and a notable innovator, the organisation is a company other US healthcare providers look to when it comes to technological development and investment. The highly fragmented North American marketplace represents excellent growth potential. CSAM Optima is well suited to such an environment, as the solution can be sold in smaller parts, it is possible to build a positive business case for customers, and its versatility ensures we can adapt it to specific needs.

New Zealand - a solution that is increasingly central to funding arrangements

In New Zealand, CSAM Optima Predict is used by Hato Hone St John Ambulance, which provides ambulance services to 90% of the population. While the solution is primarily used to optimise resource allocation and inform strategic planning, it is also integrated into the service's government funding process.

Previously, government funding was determined and awarded based on negotiations between Hato Hone St John and the New Zealand government. This often resulted in the service receiving less funding than required. Today, financing is awarded according to CSAM Optima performance models.



Hato Hone St John provides various funding packages based on performance targets and CSAM Optima modelling, and the commissioning body agrees to fund one of the packages.

The arrangement is an example of CSAM Optima informing government-level decision-making and becoming integral to those processes. Customers and commissioning authorities are utilising the solution as a scientific, unbiased and independent mediation tool to resolve conflict and facilitate collaboration. This is proving key to customer retention and growth in markets like the UK and New Zealand.

Making connections and showcasing product power

Over the past year, CSAM Public Safety had considerable success in areas where it has an established market presence. In many of these cases, previous experience using CSAM solutions acted as a catalyst for further adoption.

At Hato Hone St John, Dave Richards began using CSAM Optima when he was Head of Business Intelligence. Since becoming General Manager of Ambulance Operations, he has made it a central component in strategic and operational planning and afforded it greater prominence.



Hugh Bennett, the Assistant Director of Commissioning & Performance at the UK's Welsh Ambulance Service, adopted the solution seven years ago, after seeing its impact on other ambulance services. And, as we have already touched on, Valencia Port Authority became a CSAM CoordCom customer after gaining first-hand experience with the solution.

These examples highlight the links between market presence, the maintenance of long-term relationships and business growth.

The true value of CSAM Teams

The past year has shown that CSAM's success cannot be attributed solely to product quality. The company's regional teams are just as important an asset and CSAM customers value them highly. Their expertise and experience are invaluable to customers who want and need to work with specialists who understand the sector and the operational, organisational and technological challenges involved in public safety.

Valencia 112 and the CSAM CoordCom teams are excellent examples. Over 25 years, they have worked together to engineer a solution that is widely viewed as one of Europe's most effective and advanced emergency response systems. To do so, the teams regularly meet for collaborative workshops to exchange solution expertise and work on new features and capabilities. The close working relationship between Valencia 112's CTO, and CSAM's Solution Architect and Account Manager, has also been central to the project's success.

CSAM Optima customers also benefit directly from the work performed by CSAM Analysts. Sometimes referred to as 'embedded resources' as they work side-by-side with customers, they help users realise the solution's full potential. CSAM product teams

and the customer teams are both Public Safety experts. However, they often approach questions and issues from slightly different perspectives. CSAM's Business Analysts bridge the gap and reconcile these approaches.

Meet some of the Optima analysts bridging the gap

Tef Jansma Lead Analyst, Optima, UK

"The analysts we get with Optima are of an incredibly high quality. Tef and CSAM are working globally and are exposed to the latest public safety technologies and ideas. With CSAM Optima, you're not just buying a bit of kit. You're buying considerable intellectual power, too."

- Hugh Bennett, Assistant Director of Commissioning & Performance at Welsh Ambulance Service

Kamal Patel Senior Business Analyst, Optima, New Zealand

"Kamal has been instrumental in supporting new analysts and helping to train and upskill them. He is present in the organisation and you can give him a ring or talk to him in person at any time. He understands the organisation and relays his insight to CSAM. He knows the tool well and liaises with other CSAM experts to find solutions."

- Dave Richards, General Manager of Ambulance Operations at St John Ambulance New Zealand

Targeting continued, long-term success

For CSAM Public Safety, 2022 has been a year of continued progress. Driven by CSAM CoordCom and CSAM Optima Predict, Public Safety has consolidated its position and expanded to encompass new customers in several key markets. Renewals in the UK, North America and Spain demonstrate that customers recognise the value of these solutions, while the new contract with MedStar in the US highlights the potential for long-term growth in this promising market.

Business Areas

Public Safety

CSAM's emergency response solutions offer a complete suite of systems for the professionals who save lives in an emergency. This unique software portfolio ensures a safe and robust emergency response, assisting emergency call centre operators, dispatchers, first responders and casualty clinic staff. It also provides critical patient information to emergency room doctors.

CSAM's Public Safety portfolio also includes advanced analytics solutions with which emergency organisations can model resourcing and operational changes using best-practice event simulation. They can also leverage historical data across almost any aspect of performance. Crucially, these solutions also improve real-time decision making and prioritisation for dispatchers who manage emergencies.

These tried and tested solutions enhance public safety, delivering emergency responses that are faster, more accurate and more efficient.

Connected Healthcare

CSAM offers a range of solutions for patient data to be securely shared by healthcare professionals collaborating across different departments and organisations, as well as with patients. CSAM's application infrastructure and security components mean clients can implement complex, customized intra- and inter-hospital workflows. The solutions collate data from a variety of systems directly into patient journals, supporting healthcare professionals in their day-to-day work through an easy-to-use interface. For patients being treated at home CSAM's comprehensive, cloud-based solution means they and their healthcare team can interact easily at low cost through a web interface or mobile applications.

Women & Children's Health

With CSAM's range of maternity solutions, expectant mothers, hospital and maternity clinic staff can securely upload, access and share key medical information during pregnancy, childbirth, and infancy. These dedicated cloud-based solutions speed the flow of vital information, simplify data collection and improve risk assessment and management, and involve expectant mothers more closely in the health aspect of their pregnancy. The portfolio offers particular clinical advantages with complicated or high-risk deliveries. CSAM's offering in this domain includes a complete Assisted Reproductive Technology management system for the modern, paper-free IVF clinic.

Laboratory Information Management Systems

Trusted by more than 185 blood centres in five countries, CSAM's advanced Laboratory Information Management System comprehensively supports all aspects of blood, cell and tissue management, with full traceability from donor to recipient. It is currently used by blood donors, blood centres and laboratories for transfusions, clinical immunology, transplants and stem cell interventions.

Medical Imaging

CSAM Medical Imaging provides a secure, end-to-end system for all types of medical images, from capture and storage to sharing and archiving. The solutions have capabilities for legacy formats as well as the latest digital image innovation. With CSAM tools health professionals can collaborate easily and securely to make the best decisions for patients. These software solutions are trusted by medical organisations of all sizes - from small clinics to large regional and national imaging networks. Their innovative feature set reflects the modern workflows of health professionals, including mobile image management and secure, high-volume transfers.

Medication Management

CSAM's oncology solution uses clinically validated protocols and patient parameters to ensure safe, effective medication management for patients. The solution strengthens all aspects of medical care for cancer patients, with key information flowing seamlessly between prescribers, pharmacies, and nurses. It integrates support for all adult and paediatric cancers and cancer medications, including chemotherapy, immunotherapy, and hormone therapy and is therefore a valuable support to every area of oncology medication.

Health Analytics

CSAM's health analytics solutions improve the quality, utility, and management of medical data from collection to analysis. Using healthcare analytics, medical researchers identify and interpret patterns in healthcare data to see how efficiencies can be realised and clinical practice and outcomes improved. Our secure standardised software makes it easy for clinical researchers and other professionals in medicine and academia to gather and analyse well-managed medical data to deliver breakthrough innovations in medical practice and scientific knowledge.

Report from the Board of Directors

Operational Highlights 2022

In 2022, CSAM achieved income of 370 MNOK, growing by 12% and making it the seventh consecutive year with revenue growth. Recurring revenue grew by 13% in 2022 reaching 281 MNOK, and now represents 76% of the company's sales. The reported EBITDA for 2022 was 2 MNOK, resulting in a 1% EBITDA margin, significantly impacted by the accruals and one-offs related to the cost-reduction programme that was started in Q4-22. Adjusted for the one-offs and accruals, the EBITDA was 24.9 MNOK, resulting in a 7% EBITDA margin.

The share of revenue from operations outside the Nordics increased from 9% in 2021 to 13%, and the full-year organic growth was 8% in local currency (4% in NOK).

In Q1-22, CSAM acquired the health analytics company Carmona, further strengthening CSAM's health analytics domain. Carmona offers data analytics solutions for the life sciences sector, healthcare providers and researchers.

Throughout the year, CSAM took several steps to improve business performance and to build financial strength and flexibility to continue on its growth path. Firstly, it established domain-centric business areas to move decision-making and P&L responsibility closer to customers. Later in the year, a group-wide cost-saving programme was initiated, delivering increased profitability and cash from operations going forward, including the transition to a leaner organisational structure. The programme will deliver an annual cost-saving effect of approximately 60 MNOK.

Financial Results for the CSAM Health Group AS (Consolidated accounts)

The financial accounts have been prepared in accordance with NGAAP. Figures in brackets in the text below relate to the corresponding periods in 2021. All numbers are presented in NOK.

CSAM's consolidated revenues for 2022 amounted to 369.7 million (330.7). For the year, reported income increased by 12%.

The revenue increase was driven by a mixture of organic growth from existing business combined with acquisitions made during 2021 and 2022.

Operating profit shows a loss of -90.4 MNOK (-41.8). The corresponding calculated EBITDA decreased to 2.3 million (41.8). The reported EBITDA margin decreased to 1% (13%).

The reduced profitability is explained by the many acquisitions the company has performed during the past 24 months and the reorganisation of the company. Acquisitions overall show initially lower EBITDA margins than the Group average, and the numbers for 2022 reflects this. In general, acquisitions should be expected to have an initial dilutive effect on overall Group margins, improving to Group average within a 12 to 24-month period.

Investments in software that is expected to provide lasting recurring revenues in the future are capitalised. It is assumed that future revenues related to the capitalised amounts will at least surpass the capitalised amounts. Capex from development of software amounted to 35.8 million (23.0) in 2022, comprising 10% (7%) of total revenue. Depreciation and amortisation amounted to 88.9 million (83.7) in 2022. Following an impairment review, 3.9 million (0) is booked as impairment loss in 2022.

Intangible assets from acquisitions are amortised over a period of five years, and Goodwill from acquisitions is amortised over a period of ten years in accordance with NGAAP.

Profit before tax was -136.3 (-89.1) million for the year, and -131.6 (-86.6) after tax. The company has tax losses carried forward from previous years and expect to utilise these in the years to come, thus we expect a modest effective taxation of the Groups profits going forward.

Cash earnings from operations was 2.3 million for the year (41.8), and cash flow from operating activities amounted to 11.6 million (22.0). Cash flow from investing activities was -62 million, down from -226.1 the year before. Cash flow from financing activities was -34.6 million for the year (180.3), which primarily reflects interest paid on the bond loan, CSAM01 PRO.

The notable difference between the operating result and cash earnings from operations, is attributable to amortisations, in addition to depreciations, impairment and accruals for restructuring.

Cash and cash equivalents decreased to 196.6 million (280.9) at the closing of the year.

The notable difference between the operating result and cash earnings from operations, is attributable to amortisations, in addition to depreciations, impairment and accruals for restructuring.

Cash and cash equivalents decreased to 103.6 million (201.7) at the closing of the year.

Total assets at the end of 2022 amounted to 693.5 million (855.5). 58% (53%) of the assets are intangibles, to a large part related to the Group's active M&A strategy.

Total long-term liabilities were 520.8 million (526.7) at the end of 2022. CSAM's consolidated booked equity amounted to 28.8 million (171.7) as of 31 December 2022. This corresponds to an equity ratio of 4% (20%).

Financial Results for the CSAM Health Group AS

The financial accounts have been prepared in accordance with NGAAP. Figures in brackets in the text below relate to the corresponding periods in 2021. All numbers are presented in NOK.

Revenues for CSAM Health Group AS amounted to 193.7 million (128.2). The revenue increase was primarily driven by acquisitions, and subsequently increased sales of Professional Services, upselling and increased Service and maintenance (recurring revenue).

Operating profit shows a profit of 4.6 MNOK (-0.9).
The corresponding calculated EBITDA increased to 20.4 million (13.1).

Investments in software that is expected to provide lasting recurring revenues in the future are capitalised. It is assumed that future revenues related to the capitalised amounts will at least surpass the capitalised amounts. Capex from development of software amounted to 11.4million (5.4) in 2022, comprising 6% (4%) of total revenue. Depreciation and amortisation amounted to 11.9 million (14.0) in 2022.

Intangible assets from acquisitions are amortised over a period of five years, and Goodwill from acquisitions is amortised over a period of ten years, which is in accordance with CSAM's Accounting Principles, see also note 8.

Following an impairment review, 3.9 million (0) is booked as impairment loss in 2022. CSAM Health Group AS (the Parent) received government funding

(SkatteFUNN) for three development projects in 2022.

Profit before tax was -2.3 (-5.8) million for the year, and -2.4 (-6.7) after tax. The company has tax losses carried forward from previous years and expect to utilise these in the years to come, thus we expect a modest effective taxation of the company's profits going forward.

Cash flow from financing activities was -32.8 million for the year (180.3) which primarily reflects interest paid on the bond loan, CSAM01 PRO. Cash and cash equivalents decreased to 103.6 million (201.7) at the closing of the year. Total assets at the end of 2022 amounted to 844.6 million (853.5).

Total long-term liabilities were 494.4 million (491.4) at the end of 2022.

Booked equity amounted to 301.3 million (303.7) as of 31 December 2022. This corresponds to an equity ratio of 36% (36%).

Dividend Payment

The Board of Directors proposes that no ordinary dividend is paid based on the accounts for 2022.

Continuing Operation

With reference to the Norwegian Accounting Act §3-3a, the Board confirms its belief that conditions exist for continuing operations and that these financial statements have been prepared in accordance with the going concern principle. The confirmation is based on an estimated long-term profitable growth and the Company's equity standing and solid cash position.

Operational and Financial Risks

The Group is exposed to various risks and uncertainties of operational, regulatory, market and financial character. Internal controls and risk management are an integrated part of all CSAM organisational business processes and of achieving the Company's strategic and financial objectives. The below listing highlights what the Company currently regards as the main risk factors but does not in any way constitute a full or complete overview of all risks that the Company may be exposed to.

Despite the Group's focus on reducing risks through internal controls and risk management, there will still be risk factors that cannot be adequately handled through preventative measures.

Operational Risks

The Group has a broad customer base, and revenues are rooted in hundreds of contracts with different customers and different products. While this reduces the dependency on specific customer or contract, there is a risk that the Group might fail to accurately forecast its ability to deliver software according to agreed contractual schedule and quality. Professional Services may not be delivered within appropriate quality or timescales or could be implemented poorly and fail to deliver savings to the customers.

If the Group underestimates the cost, complexity or time requirements to deliver on a contractual obligation, it may incur losses in the form of penalties and/or reduced future income. Such delays or failures may have an adverse effect on the Group's business, results of operations and financial conditions, and on its reputation as a trusted provider of high-quality niche software solutions.

The market in which the Company operates is strictly regulated and increasingly so, most importantly through the EU wide MDD/MDR and GDPR regulations. There is a risk that the Company fails to comply with the relevant regulation or that, despite rigorous testing before release, the software malfunctions and thus breaches the expectations by its users. This may have negative financial as well as reputational consequences.

The Group is dependent on its management and key personnel and the ability to retain and attract new, qualified personnel. The Group must attract, train and retain appropriate numbers of highly qualified professionals with diverse skills, in order to serve customers' needs and grow the Group's business. Management is a crucial factor for the performance and results of the Group and the loss of any key individual may adversely affect the Group's performance.

The Group has a strategy of growing in part by acquisitions and has made and may make material acquisitions in the future. Acquisitions may involve significant risks, including but not limited to: difficulties in the assimilation or integration of the operations, services and corporate culture of the acquired companies; failure to achieve expected synergies and other benefits; and diversion of management's attention from other

business concerns. In addition, further acquisitions would likely result in the incurrence of additional debt.

Successful growth through acquisitions is dependent upon the Group's ability to identify suitable acquisition targets, conduct appropriate due diligence, negotiate transactions on favourable terms and ultimately complete such acquisitions and integrate acquired entities within the Group. The Group's assessment of and assumptions regarding acquisition targets could prove to be incorrect and actual developments may differ significantly from expectations. There is also a risk that the Group may incur significant losses on its acquisitions. Any unsuccessful acquisitions may have a material adverse effect on the business, result of operations, cash flows, financial conditions, and prospects for the Group.

Financial Risk

The Group has high leverage and may incur additional indebtedness in the future, also in the form of vendor loans (related to acquisitions). The Group may not be able to repay all or part of the indebtedness, or alternatively, refinance all or part of the indebtedness on commercially reasonable terms. Further, under the bond terms, the Group will only be allowed to make distributions if it complies with certain predefined leverage ratios. Increased debt levels may also restrict the Issuer's ability to borrow additional capital on a timely basis to fund acquisition opportunities as they arise.

The Group is dependent on having access to long-term funding and may in the future require additional funding in the form of either debt or equity to successfully execute its M&A-strategy and to finance further growth. There can be no assurance that the Group will be able to raise additional growth capital necessary to execute on its M&A strategy.

The Group's operations are conducted in the Nordics, other European countries, as well as in Asia, North America, and Oceania. Operations in the Group's markets are subject to risks inherent in international business activities, including, but not limited to: foreign currency fluctuation; varying geopolitical conditions; cultures and business practices in different countries; overlapping of different tax structures; accounting and reporting requirement compliance; changing and, in some cases, complex or ambiguous laws and regulations; and litigation claims and judgements. The Group does not conduct business with any customer in Russia.

The Group has subsidiaries that operates in various currencies and is subject to tax exposure in various currencies. The Group's local operations are reported in the applicable foreign currencies and then translated into NOK at the applicable foreign currency exchange rates for inclusion in the Group's consolidated financial statements. Exchange rates for currencies may fluctuate in relation to the NOK and these fluctuations may have an adverse effect on the Group's operating results when foreign currencies are translated into NOK.

The Public Sector is the Group's main customer group, most of which are in the Nordics and Europe. A limited part of the customers is to be found in the private sector, some of which can be in a more vulnerable financial position than hospital customers in the public sector, and thus the Group has a credit exposure to these customers where part or all of accounts receivable can be at risk.

The Organisation

CSAM has established itself as a leading Nordic-based software provider offering niche solutions to healthcare providers and emergency services. The company combines best-in-class innovative technology with deep expertise in the domains it serves. CSAM's diverse product portfolio includes innovative solutions in connected healthcare, women and children's health, laboratory information management systems, medication management, medical imaging, health analytics and public safety.

CSAM's stronghold is centred around its unique software solutions, building a solid foundation for business models with strong recurring revenue and long-lasting client relationships. Adjacent to these software solutions, there is a symbiotic relationship with more narrow revenue streams from consulting, training and specialised hardware, such as ambulance tablets running CSAM software.

CSAM has seen solid acquisition-led growth with its focused M&A strategy of identifying, buying and integrating companies that provide specialised software within the domains of healthcare and emergency services. As one of the only Nordic consolidators in this very fragmented market, CSAM selectively targets companies that meet the requirements of having stable recurring revenue from existing customers, owning their Intellectual property, and teams with deep expertise in their niche. Acquired businesses benefit from the Group's expertise and scale, and all new acquisitions are fully integrated into CSAM's organisation with its Buy, Integrate and Build (BIB) model.

CSAM is headquartered in Oslo, Norway with local offices in Sweden, Denmark, Finland, UK, Lithuania, Spain, New Zealand, the United States and the Philippines. CSAM delivers software and services to almost all hospitals in the Nordic region, and is expanding its geographical reach, primarily through selected acquisitions. CSAM Health Group AS is listed on the Oslo Stock Exchange, Euronext Growth (CSAM) and Nordic ABM.

CSAM had 317 (288) employees at the end of 2022. CSAM aims to have a balanced representation of gender, age, race and religion. The proportion of women is 29% (27%) in the Group. The Board consists of 6 people, 3 women and 3 men. No incidents of injury or accidents in the workplace were reported during 2022. In the Norwegian organisation, absence due to sick leave averaged 4,9 % (0.5%) in 2022.

CSAM Health Group AS and subsidiaries has a «Directors & Officers Liability Insurance» with AIG. All board members and the managing director of CSAM Health Group AS are covered. It is a general liability insurance and is limited to 50 MNOK. The insurance will cover but is not limited to the following: Assets & Liberty Extradition Expenses, Assets & Liberty Personal Expenses, Reputation Expenses, Insolvency Hearing Cover, Circumstance/ Claim Mitigation: Mitigation Costs, Prosecution Costs and Professional Fees, Derivative Investigation Hearing Costs and Emergency Costs.

Corporate Social Responsibility, the Environment and Employees

CSAM aspires to achieve sustainable development by striking a good balance between financial results, value creation, sustainability, and corporate social responsibility (CSR). The Company's objective is to maximize the positive impact the Company has on society by enabling efficient healthcare through its many software solutions. In pursuing our business objectives, we aim to be a responsible partner to our communities, acting with integrity towards our customers, employees, business partners and shareholders, as well as society.

As a software company, the Group's operations do not directly pollute the environment. To minimise our carbon footprint, to the extent possible, physical travel is replaced by video conferences. We seek to locate our offices close to public transportation.

Diversity and equal opportunity

CSAM promotes equality in the workplace and focuses on hiring and promoting talent independent of race, colour, gender, sexual orientation, age,

disability, language, religion, employee-organisation affiliation, political or other opinion, national or social origin, property, birth or other status.

The Company shall be a professional workplace with an inclusive working environment, free from discrimination. Refer to our report on diversity and equal opportunities for details of our work to prevent discrimination and promote equality.

Download: [Diversity and Equal Opportunity Report](#)

Life-Work Balance

CSAM strives to make it possible for employees of either gender to combine their work and private life, and therefore offers leave arrangements, home office solutions and part-time positions and other flexible work arrangements to support this objective.

Business Ethics

We pursue mutually beneficial long-term relationships with customers, partners and suppliers, and promote the application of these principles while doing so. We make decisions based on our ability to promote these principles effectively, and this is an important factor in decisions regarding whether to enter into or remain in such relationships.

CSAM requires that the Company's business partners have appropriate ethical standards that is at a minimum of those defined in the Company's Statement of General Business Principles and other relevant policies.

We insist on honesty, integrity and fairness in all aspects of our business and expect the same of all those with whom we do business. The direct or indirect offer, payment, soliciting or acceptance of bribes in any form is unacceptable. Employees must avoid conflicts of interest between their private financial activities and their part in the conduct of company business. All business transactions on behalf of a CSAM company must be reflected accurately and fairly in the accounts of the company, in accordance with established procedures, and be subject to audit.

Corporate Governance

CSAM's corporate governance policy is based on the Norwegian Corporate Governance Code in accordance with NUES the Norwegian Code of Practice for Corporate Governance (Norwegian: "Norsk anbefaling for eierstyring og selskapsledelse"), issued by the Norwegian Corporate Governance Board, most recently revised on 14 October 2022. CSAM Health Group AS is incorporated and registered in Norway and is subject to Norwegian law.

Responsible Sourcing

CSAM Health Group supports the Ten Principles of the United Nations Global Compact on human rights, labour rights, environment, and anti-corruption. To read more about CSAMs efforts related to transparency, fundamental human rights and decent working conditions, refer to our report on Responsible Sourcing.

Download: [Responsible Sourcing Report](#)

Subsequent events

At the end of 2022, after five acquisitions in the preceding 24 months, CSAM identified that there were additional synergies to be realised by streamlining the operating model for the individual Business Areas, as well as Common Service functions. In Q1-23 the company completed the implementation of a group-wide cost-saving programme.

Outlook 2023

The effect of the abovementioned programme is a cost-saving of 60 MNOK annually, which will improve CSAM's financial flexibility to continue its growth. We believe that these cost savings, coupled with assumed continued organic growth within our previously communicated 5-10% range and continuation of limited churn, will bring the financial performance of the current operations close to the target EBITDA-margin of 30% from the third quarter of 2023. Any new acquisition, particularly if of some magnitude, should be expected to dilute the margin.

Forward Looking Statements

Certain statements included in this report may be deemed to contain forward-looking information, including, but not limited to, information relating to forecasts, projections and estimates, statements of CSAM management concerning plans, objectives and strategies, such as investments, divestments, other projects, cost reductions and profit objectives, margins, and growth rates.

The report may include qualified statements such as "assumed", "believed", "expected", "scheduled", "targeted", "planned" or similar.

Although we believe that the expectations reflected in such forward-looking statements are reasonable, they are based on information available at the time of the release of this report and such forward-looking statements are based on a number of assumptions and forecasts that, by their nature, involve risk and uncertainty, and actual results could differ materially from those indicated by these statements.

Declaration by the Board of Directors and CEO

We hereby confirm that, to the best of our knowledge, that the financial statements for the period from 1 January to 31 December 2022 have been prepared in accordance with NGAAP, and that the information in the financial statements gives a true and fair view of the Group's assets, liabilities, financial position and profit & loss taken as a whole.

The Board of Directors of CSAM Health Group AS Oslo, 17th April 2023.

**Åse Aulie Michelet, Chair**

Handwritten signature of Åse Aulie Michelet in black ink.

**Marianne Elisabeth Johnsen, Vice Chair**

Handwritten signature of Marianne Elisabeth Johnsen in black ink.

**Hans Erik Robbestad, Board Member**

Handwritten signature of Hans Erik Robbestad in black ink.

**Gunnar Bjørkavåg, Board Member**

Handwritten signature of Gunnar Bjørkavåg in black ink.

**Mats Larson, Board Member**

Handwritten signature of Mats Larson in black ink.


**Kjellrun Borgmo, Board Member**

Handwritten signature of Kjellrun Borgmo in black ink.

**Sverre Flatby, CEO**


Handwritten signature of Sverre Flatby in black ink.

Financials




DISTRIBUTION OF SALES, PER COUNTRY

- Sweden 46%
- Norway 21%
- Finland 9%
- Denmark 11%
- Rest of the World 13%




DISTRIBUTION OF SALES, PER BUSINESS AREA

- Public Safety 42%
- Connected Healthcare 13%
- Women & Children's Health 12%
- LIMS 13%
- Medical Imaging 7%
- Medication Management 4%
- Health Analytics 7%
- Other 2%



DISTRIBUTION OF SALES, PER INCOME TYPE

- Recurring Revenue 76%
- Professional Services 17%
- Hardware Sales 3%
- License sales 2%



EMPLOYEES PER YE 2022 (TOTAL 317)

- Nordics 70%
- Asia 16%
- Europe 7%
- Oceania 6%
- Americas 1%

INCOME STATEMENT (NOK THOUSAND)

CSAM Health Group AS			CSAM Health Group AS, consolidated			
2022	2021	Note		Note	2022	2021
4 504	1 307		License sales		12 327	10 553
66 419	62 839		Service and maintenance		281 266	249 637
121 305	62 683	2,5	Professional Services		64 157	52 450
-	-		Hardware sales		8 919	16 663
11	157		Other operating income		1 488	140
192 239	126 986	2,5	Total sales revenue	2	368 158	329 444
1 498	1 212	16	Government grants (Skattefunn)	16	1 498	1 212
193 737	128 198		Total operating revenue		369 656	330 656
3 354	3 424		Cost of Goods and Services		33 380	35 368
82 226	59 307	3	Salary and personnel	3	251 584	190 766
9 811	12 913	8	Amortization of goodwill and licenses	8	85 076	81 328
3 891	-	8	Impairment of goodwill and licenses	8	3 891	-
2 093	1 096	9	Depreciation	9	3 790	2 325
82 562	52 390	4,5	Other operating cost	4	69 084	62 691
5 188	-	3,4	Restructuring	3,4	13 301	-
189 125	129 130		Total operating expenses		460 105	372 478
4 613	-932		Operating profit/(loss)		-90 449	-41 822
30 083	21 921	5	Interest income from enterprises within the same group		-	-
1 960	5		Other interest income		1 968	-
622	543	5	Interest cost to enterprises within the same group		-	-
37 138	26 639	6	Interest expenses	6	37 198	26 697
1 211	(429)	6	Other finance expenses	6	10 652	20 604
-6 927	-4 827		Net financial items		-45 883	-47 289
-2 314	-5 759		Profit before tax		-136 332	-89 110
125	964	7	Tax	7	-4 733	-2 547
-2 440	-6 723		Profit/(loss) for the year		-131 598	-86 563

BALANCE SHEET (NOK THOUSAND)

CSAM Health Group AS			CSAM Health Group AS, consolidated			
31.12.22	31.12.21	Note	Note	31.12.22	31.12.21	
Non-current assets						
Intangible fixed assets						
28 372	28 497	7	Deferred tax assets	7	30 031	41 199
1 375	4 364	1, 8	Goodwill	1, 8	77 216	92 122
24 183	30 416	1, 8	Intangible assets	1, 8	294 796	320 066
53 929	63 277		Total intangible assets		402 043	453 387
Tangible fixed assets						
4 328	4 909	9	Fixed durable assets	9	9 138	8 129
4 328	4 909		Total tangible fixed assets		9 138	8 129
Financial non-current assets						
243 943	158 290	1, 10	Investments in subsidiaries	-	-	
-	84 153	5	Loans to subsidiaries	-	-	
243 943	242 444		Total financial non-current assets		-	-
302 201	310 629		Total non-current assets		411 181	461 516
Current assets						
-	-		Inventories	327	7	
13 219	15 348	11	Accounts receivables	11	51 151	81 514
6 831	8 117	12	Other receivables	12	34 319	31 639
418 771	317 752	5	Short term receivables, subsidiaries	-	-	
103 569	201 661	13	Cash and liquid assets	13	196 566	280 855
542 388	542 879		Total current assets		282 363	394 015
844 589	853 508		Total assets		693 544	855 531

BALANCE SHEET (NOK THOUSAND)

CSAM Health Group AS			CSAM Health Group AS, consolidated		
31.12.2021	31.12.2022	Note	Note	31.12.2021	31.12.2022
Equity					
Paid-in Equity					
2 097	2 097	14	Share capital	14	2 097
299 165	301 605		Share premium reserve		26 676
	-		Other reserves		169 591
301 262	303 702	15	Total equity	15	28 773
Non-current liabilities					
-	-	1,7	Deferred tax liability	1,7	26 406
494 426	491 358	6	Bond Loan	6	491 358
494 426	491 358		Total non-current liabilities		520 832
Current liabilities					
2 449	4 237		Accounts payable		11 502
15 777	9 479		Public duties payable		20 359
8 067	7 101	5	Short term liabilities, subsidiaries		34 522
22 608	37 631	16	Other current liabilities	16	24 037
48 901	58 448		Total current liabilities		143 939
844 589	853 508		Total equity and liabilities		157 171
					693 544
					855 531


The Board of Directors of CSAM Health Group AS Oslo, 17th April 2023.



Åse Aulie Michelet
Chair




Hans Erik Robbestad
Board Member



Marianne Elisabeth Johsen
Vice Chair and Board Member



Gunnar Bjørkavåg
Board Member



Mats Larson
Board Member



Kjellrun Borgmo
Board Member



Sverre Flatby
CEO

CASH FLOW (NOK THOUSAND)

CSAM Health Group and CSAM Health Group AS, consolidated accounts

CSAM Health Group AS			CSAM Health Group AS, Consolidated	
2022	2021		2022	2021
-2 314	-5 759	Profit/(loss) before taxation	-136 332	-89 110
6 927	4 827	Net financial items	45 883	47 289
15 795	14 009	Depreciation, amortisation and impairment	92 757	83 653
20 408	13 077	Cash earnings from operations	2 308	41 831
2 130	-130	Changes in accounts receivables	28 253	-28 000
-1 788	2 628	Changes in accounts payables	-7 971	8 883
-13 737	11 435	Changes in other current receivables/liabilities	-16 222	-5 692
-	2 912	Changes in prepayments from customers	-	2 920
6 298	831	Changes in public duties payable	10 391	3 942
3 538	-	Taxes	-5 123	-1 903
16 849	30 753	Cash flow from operating activities	11 635	21 981
-4 479	-5 352	Capital Expenditure IP	-35 777	-22 974
-1 512	-4 414	Capital Expenditure other	-6 077	-5 660
-	-	Acquisitions	-20 122	-197 456
-74 053	-279 673	Loans to subsidiaries	-	-
-80 044	-289 438	Cash flow from investing activities	-61 976	-226 090
-	203 895	Change in Debt	-480	203 895
-32 800	-23 547	Net interest and financial fees	-34 130	-23 547
-32 800	180 348	Cash flow from financing activities	-34 610	180 348
-95 996	-78 337	Net change in cash and cash equivalents	-85 015	-23 761
201 661	263 018	Cash and cash equivalents at start of the period	280 855	304 616
-	16 980	Cash from mergers	-	-
816	-	FX adjustments	725	-
103 569	201 661	Cash and cash equivalents at end of the period	196 565	280 855

Financial Notes

Accounting principles

CSAM Health Group AS is listed on the Oslo Stock Exchange, Euronext Growth (CSAM) and the bond is listed on Nordic ABM.

CSAM's headquarters are in Oslo, Norway.

Ownership and company structure

The company was established on 14 March 2012 by one part of previous owners who had used shares in this company as non-cash contributions in CSAM Health Group AS. At the same time, the company acquired the remaining 49.38% of the shares in CSAM Health AS from the other owners, so that the company owned 100% of the shares in CSAM Health AS.

CSAM Health Group AS owns 100% of the shares in CSAM Sweden AB, in Sweden.

CSAM Health Group AS owns 100% of the shares in CSAM Finland Oy, in Finland.

CSAM Health Group AS owns 100% of the shares in CSAM (UK) Ltd, in England.

CSAM Health Group AS owns 100 % of the shares in Aygo AS, in Norway.

CSAM Health Group AS owns 100 % of the shares in CSAM Denmark A/S, in Denmark.

CSAM Health Group AS owns 100 % of the shares in CSAM Spain, S.L.

CSAM (UK) Ltd owns 100% of the shares in CSAM Health UK Ltd in England.

CSAM Finland Oy owns 100 % of the shares in CSAM Kibi Finland Oy in Finland.

CSAM Sweden AB owns 100 % of the shares in CSAM Karlstad AB in Sweden.

CSAM Sweden AB owns 100 % of the shares in CSAM Public Safety AB, in Sweden.

CSAM Sweden AB owns 100 % of the shares in CSAM MedSciNet AB, in Sweden, with subsidiaries in Great Britain and Lithuania.

CSAM Public Safety AB owns 100 % of the shares in CSAM New Zealand Ltd, in New Zealand, with subsidiaries in Great Britain, Australia and USA.

CSAM MedSciNet AB owns 100 % of the shares in CSAM Carmona AB, in Sweden.

Aygo AS owns 99,995% of the shares in CSAM Philippines inc, in the Philippines.

Accounting principles

The Annual financial statements, together with consolidated financial statements, have been prepared under the Norwegian accounting act of 1998 and generally accepted accounting principles in Norway.

Subsidiaries/associated companies

Investments made by the parent company in the subsidiary are assessed according to the cost method. The investment is valued at the acquisition cost of the shares unless impairment has been necessary. Impairment to fair value is carried out when the impairment is attributable to causes not deemed to be temporary, and where such action is deemed necessary per generally accepted

accounting practice. Impairments are reversed when the basis for the impairment no longer exists. Dividends and other distributions are recognised as income in the same year that they are proposed in the subsidiary. If the dividend exceeds the share of retained earnings after the acquisition, the excess share is deemed to represent repayment of the invested capital, and the distributions are deducted from the value of the investment in the balance sheet.

Consolidation principles

The consolidated financial statements comprise the parent company CSAM Health Group AS and companies in which the company has a controlling influence, directly or indirectly, regardless of company type. The consolidated accounts are prepared according to uniform principles for the entire group. Internal transactions, profits, receivables, and liabilities are eliminated. The cost price for shares and shares in subsidiaries is eliminated in the consolidated financial statements against the equity in the subsidiary measured at the time of establishment or purchase (acquisition method). Excess values are allocated to the assets concerned and are amortised over the estimated economic life of the assets. An excess value that cannot be attributed to specific assets is classified as goodwill and amortised over the expected economic life.

Translation of foreign subsidiaries

For the translation of foreign subsidiaries, balance sheet items are translated at the exchange rate on the balance sheet date. Income statement items are translated at the average exchange rate for the financial year. Currency differences on translation are recognised directly in equity.

Business combinations and goodwill

Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, measured at acquisition date fair value, and the amount of any non-controlling interest in the acquiree. For each business combination, the acquirer measures the non-controlling interest in the acquiree either at fair value or at the proportionate share of the acquiree's identifiable net assets. Acquisition-related costs are capitalised as part of the cost price of the shares or assets acquired. When CSAM acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. Any contingent consideration to be transferred will be recognised at fair value at the acquisition date. Contingent consideration classified as an asset or liability is measured at fair value at each reporting date with changes in fair value recognised in the income statement.

Significant accounting judgements, estimates and assumptions

The preparation of the Group's consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the reporting date. However, uncertainty about these assumptions and estimates could result in outcomes that require a material

adjustment to the carrying amount of the asset or liability affected in future periods.

When preparing the annual accounts per good accounting practice, the best estimate is used based on the information that is available when annual accounts are presented. Consequently, actual figures may differ from the estimates. The effects of changes in accounting estimates are recognised in the income statement in the period in which the estimate changes. Contingent liabilities which are probable and quantifiable are expensed on an ongoing basis.

The general rule for valuation and classification of assets and liabilities

Assets intended for permanent ownership or long-term use are classified as fixed assets. Other assets are classified as current assets. Receivables to be repaid within one year are classified as current assets. Similar criteria are used when classifying current and long-term liabilities.

Fixed assets are recorded at acquisition cost with deductions for planned depreciation. If the fair value of fixed assets is lower than recorded value, and the write-down is not deemed to be temporary, the assets are written down to fair value.

Current assets are valued at the lower of cost and fair value.

Receivables

Trade and other receivables are recognised at nominal value in the balance sheet, reduced by provisions for expected bad debts. Bad-debt provisions are based on an individual assessment of each receivable.

Functional currency and presentation currency

The consolidated financial statements are presented in Norwegian kroner (NOK), which is CSAM Health Group AS's functional currency. Transactions in foreign currencies are initially recorded in the functional currency at the exchange rate the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rate at the reporting date. All exchange differences are recognised in the income statement. Non-monetary items that are measured at historical cost in foreign currency are translated using the exchange rates at the dates of the initial transactions.

CSAM Health Group has foreign entities with functional currency other than NOK. At the reporting date, the assets and liabilities of foreign entities with functional currencies other than NOK are translated into NOK at the rate of exchange at the reporting date and their income statements are translated at the average exchange rates for the year. The translation differences arising from the translation are recognised in the income statement.

Goodwill and fair value adjustments of carrying amount of assets and liabilities arising from the acquisition of a foreign operation, are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.

Intangible assets**Research and development cost**

Research costs are expensed as incurred. Development expenditure incurred on an individual project is recognised as an intangible asset when the Group can demonstrate all of the following:

- The technical feasibility of completing the intangible asset so that it will be available for use or sale
- Its intention to complete and its ability to use or sell the asset
- Its ability to use or sell the intangible asset
- How the asset will generate future economic benefits
- The availability of adequate, technical, financial and other resources to complete the development and to use or sell the intangible asset
- The ability to measure reliably the expenditure during development.

Following the initial recognition of the development expenditure, the cost model is applied requiring the asset to be carried at cost less any accumulated amortisation and accumulated impairment losses. Any capitalised expenditure is amortised over the period of the expected future sales from the related product. Amortization starts when the development process is completed. A product version is amortised from the day the product is considered ready for sale, and one or more customers have approved the installation of the solution.

The carrying value of development costs is reviewed for impairment when an indicator of impairment arises during the reporting year indicating that the carrying value may not be recoverable. Gains and losses arising from divesting of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the income statement when the asset is derecognised.

Internally generated intangible assets, excluding capitalised development costs, are not capitalised but are expensed as occurred.

Identifiable intangible assets acquired in business combinations

The cost of intangible assets acquired in a business combination is fair value as at the date of acquisition. Values related to contracts and customer relationships are identified and recorded as identifiable intangible assets. The fair value of contracts and customer relationships are calculated considering the estimated future recurring revenues from the customers in the acquired operations at the date of the acquisition. The fair value of tax amortisations is considered in the recorded value of contracts and customer relationships. Any deferred tax liabilities related to the recorded contracts and customer relationships are calculated at nominal values and the difference between the fair value of the tax amortisations and the corresponding deferred tax liabilities are recorded as a part of goodwill.

Technology/software and customer relationships acquired are capitalised at fair value as at the date of acquisition. Following initial recognition, the cost model is applied to this class of intangible assets. Purchased technology and contract and customer relationships have 5 - 10 years of useful life and

are amortised on a straight-line basis over their useful life. The depreciable amount is determined after deducting its residual value (only where there is an active market for the asset). Useful life and residual value are reviewed at least annually and reflect the pattern in which the benefits associated with the asset are consumed. A change in the useful life or depreciation method is accounted for prospectively as a change in accounting estimate.

Impairment of intangible assets

The carrying values of intangible assets with finite useful life are reviewed for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. If any such indication exists and where the carrying values exceed the estimated recoverable amount, the assets or cash-generating units are written down to their recoverable amount. The recoverable amount of intangible assets is the greater of fair value less cost to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax rate that reflects current market assessment of the time value of money and the risks specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognised in the income statement.

Divestment of intangible assets

An item of intangible assets is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Gains or losses on the sale or disposal of intangible assets are recorded as other income and other operating costs respectively in the year the item is derecognised.

Goodwill / Badwill

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred. If the fair value of the net assets acquired is in excess of the aggregate consideration transferred, CSAM re-assesses whether it has correctly identified all of the assets acquired and all of the liabilities assumed and reviews the procedures used to measure the amounts to be recognised at the acquisition date. If the reassessment still results in an excess of the fair value of net assets acquired over the aggregate consideration transferred, then this result in the recognition of badwill to be amortised over a maximum of five years. Goodwill and badwill are presented net in the balance sheet. After initial recognition, goodwill is measured at cost less any accumulated amortisation and impairment losses. Where goodwill has been allocated to a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal of the operation in the consolidated financial statements. Goodwill disposed of in this circumstance is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained.

Impairment of goodwill

Goodwill is tested for impairment if events or changes in circumstances indicate that the carrying value may be impaired, by comparing the carrying amount of the unit, including the goodwill, with the recoverable amount of the unit. As at the acquisition date, any goodwill acquired is allocated to each of the cash-generating units, or groups of cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities are assigned to those units or groups of units. Where recoverable amount of the cash-generating unit is less than the carrying amount, an impairment loss is recognised. The recoverable amount of a cash-generating unit is the higher of its fair value less costs to sell and its value in use. Value in use is the present value of the future cash flows expected to be derived from the cash-generating unit.

Cash-generating units

A cash-generating unit is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. In identifying whether cash inflows from an asset (or group of assets) are largely independent of the cash inflows from other assets (or groups of assets), the management considers various factors including how management monitors the entity's operations (such as by product or business areas, entity, or geographical areas).

Taxes

The tax expense in the income statement comprises both taxes payable for the period and changes in deferred tax liabilities/benefits.

Deferred taxes

Deferred income tax is provided using the liability method on temporary differences at the statement of financial position date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred tax liabilities are recognised for all taxable temporary differences, except where the deferred tax liability arises from the initial recognition of goodwill. Deferred income tax assets are recognised for all deductible temporary differences, carry-forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry-forward of unused tax credits and unused tax losses can be utilised

Unrecognised deferred income tax assets are reassessed at each balance sheet date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the balance sheet date. Deferred tax assets and deferred

tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Financial debt

Loans are recognised initially at fair value, net of directly attributable transaction costs. In subsequent periods, loans are recognised at amortised cost using the effective interest method. The difference between the loan amount paid (principal at the time of withdrawal, transaction costs deducted) and the redemption value is recognised in the income statement over the term of the loan as part of the loan's effective interest cost. Loans are classified as short-term unless the company/group has an unconditional right to postpone settlement of the liability for at least 12 months after the balance sheet date.

Sales revenues

CSAMs revenues mostly consist of Software related income. Some consultancy services are provided to customers in conjunction with installation, training and integration in the customer's operating environment. In addition, there is some sale of specialized hardware used to run CSAM's software, e.g. special tablets used in ambulances.

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received, including discounts. The Group's customers are mainly hospitals in the Nordics.

Some contracts contain several commitments. For the contracts that contain several components, the revenue is distributed proportionally to the different components of the contract. In general, invoices are paid within 30-90 days from issuance.

License Sales

Most sales are made according to the classic "license and maintenance" model and installed on premise. License Sales is classified as a software license where the customer is provided with a right to use the software as it is when made available to the customer. Revenues from this license is recognised at the point in time when the installation of the software passes contractual milestones.

Recurring Revenue (Service & Maintenance)

This type of income is related to the fact that the software is installed at the customer's and he has the right to use the software according to the license agreement. A small portion of CSAM's recurring revenue is related to software sold as a cloud service license ("Software as a Service") which entitles the customers to use the software together with the Group's IP and production network over the contract period. Recurring revenues are recognised over time on a straight-line basis over the year. Invoices are typically generated on an annual, semi-annual or quarterly upfront basis. A minor part of such revenues are invoiced monthly in arrears.

Professional Services

Revenue from the sale of Professional Services (i.e. consultancy) consists of services such as service and configuration of products, these are reported during the period of which the service is provided, measured on a percent of completion basis for fixed contracts or routinely for ongoing routine deliveries.

Hardware Sales

Sales of hardware is typically recognised as income when the physical product is delivered at the customer's site.

Restructuring cost

Provisions for restructuring costs will be recognised if the Company has, within the reporting period, published or initiated a restructuring plan, which identifies which parts of the Company and approximately how many employees will be affected, the actions that will be taken and when the plan will be implemented. Provisions are recognised only for costs that cannot be associated with future earnings. Costs related to restructuring are presented on a separate line in the income statement

Construction contracts

Contracts with customers on fixed terms are viewed as constructions contracts, and recognised by the percentage of completion method. When the outcome of a construction contract can be estimated reliably, revenue and costs are recognised in proportion to the stage of completion of contract activity. In estimating the outcome of a contract, we consider the contract revenue, the stage of completion, and the costs to complete the contract. If the outcome cannot be estimated reliably, no profit is recognised. Instead, contract revenue is recognised only to the extent that contract costs incurred are expected to be recoverable and contract costs expensed as incurred. The stage of completion of a contract can be determined in a variety of ways - including the proportion that contract costs incurred for work performed to date bear to the estimated total contract costs, surveys of work performed, or completion of a physical proportion of the contract work, e.g. by defined milestones.

Contract balances**Contract assets**

A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If the Group performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognised for the earned consideration that is conditional.

Trade receivables

A receivable represents the Group's right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due).

Contract liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before CSAM transfers goods or services to the customer, a contract liability is recognised when the payment is made, or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Group performs under the contract.

Government grants

CSAM Health Group AS receives government grants from "SkatteFUNN" related to research and development. A part of the yearly grant, equivalent to the sum of manhours recognised as work in progress of the product under development that has received the grant, is recognised as unearned income, and amortised over five years from the year after the grant. This part of the grant is recognised as other income. The remaining grant is recognised as a reduction of personnel expenses or operating costs depending on which costs are the basis for the grant, in accordance with Norwegian accounting regulation.

Pensions

CSAM Health Group is required to have a contribution plan in accordance with the Norwegian Law on Required Occupational Pension. The company's pension scheme meets the requirements for all employees in Norway. In addition, voluntary pension agreements have also been signed in the subsidiaries, where each company participates with part of the contributions.

Related parties

CSAM Health Group AS, as well as the board and the management of the company, are considered to be group's related parties. Furthermore, the subsidiaries of CSAM Health Group AS are also considered as related parties. All transactions with related parties are based on the arm's length principle.

Cash and cash equivalents

Cash and cash equivalents include cash, bank deposits, and other current liquid investments. Restricted cash is included as cash and cash equivalents. For the purpose of the consolidated cash flow statement, cash and cash equivalents consist of cash and cash equivalents as defined above.

Cash flow statement

The cash flow statement has been prepared following the indirect method.

Events after the balance sheet date

New information on the company's financial position on the statement of financial position which becomes known after the balance sheet date and which provides evidence of conditions that existed at the balance sheet date is recorded in the annual accounts. Events after the balance sheet

date that are indicative of conditions that arose after the balance sheet date and that do not affect the company's financial position on the statement of financial position but which will affect the Company's financial position in the future are disclosed if significant. Refer to Note 18 for events after balance sheet date which are relevant for the current year.

Review of preliminary Purchase Price Allocations

CSAM Health Group has reviewed the preliminary Purchase Price Allocations from the acquisitions of Carmenta, MedSciNet and Optima Group which took place in 2021. In accordance with Norwegian Accounting Standard 17: Acquisitions and Consolidated Financial Statements, the effect resulting from this review are considered in the accounts as if present at the time of the acquisitions. All effects for the Income Statement, Balance Sheet and Cash Flow Statement of 2021 are explained per line item in the tables below. The presentation of the numbers for 2021 has been changed accordingly in the Consolidated Annual Statements of CSAM Health Group of 2022.

Refer to tables in Accounting Principles page 50-53 to see the effect of reviewed purchase price allocation on Income Statement, Balance Sheet and Cash Flow Statement of 2021.

**Review of preliminary Purchase Price Allocations -
Income Statement of 2021**
CSAM Health Group, consolidated

NOK thousand	Note	(Reviewed)		(Reported)
		Full-year 2021	Change 2021	Full-year 2021
License sales		10 553		10 553
Service and maintenance		249 637		249 637
Professional Services		52 450		52 450
Hardware		16 663		16 663
Other operating income		140		140
Total sales revenue		329 444		329 444
Government grants (Skattefunn)		1 212		1 212
Total operating revenue		330 656		330 656
Cost of Goods and Services		35 368		35 368
Salary and personnel		190 766		190 766
Amortisation of goodwill and licenses	8	81 328	2 284	79 044
Depreciation		2 325		2 325
Other operating cost		62 691		62 691
Total operating expenses		372 477	2 284	370 193
Operating profit/(loss)		-41 822	-2 284	-39 537
Interest expenses		26 697		26 697
Other finance expenses		20 604		20 604
Net financial items		-47 289		-47 289
Profit before tax		-89 110	-2 284	-86 826
Tax	7	-2 547	-4 845	2 297
Profit/(loss) for the year		-86 563	2 560	-89 123

**Review of preliminary Purchase Price
Allocations - Balance Sheet of 2021**
CSAM Health Group, consolidated

NOK Thousand	Note	(Reviewed)		(Reported)
		31/12/21	Change	31/12/21
Non-current assets				
Intangible fixed assets				
Deferred tax assets		41 199		41 199
Goodwill	8	92 122	28 142	63 980
Intangible assets	8	320 066	12 257	307 808
Total intangible assets		453 387	40 399	412 987
Tangible fixed assets				
Fixed durable assets		8 129		8 129
Total tangible fixed assets		8 129		8 129
Total non-current assets		461 516	40 399	421 116
Current assets				
Inventories		7		7
Accounts receivables		81 514		81 514
Other receivables		31 639		31 639
Short term receivables, subsidiaries		-		-
Cash and liquid assets		280 855		280 855
Total current assets		394 015		394 015
Total assets		855 531	40 399	815 132

Equity		(Reviewed)		(Reported)
Paid-in Equity		31/12/21	Change	31/12/21
Share capital		2 097		2 097
Share premium reserve	15	169 591	5 085	164 506
Other reserves				
Total equity		171 688		166 603
Non-current liabilities				
Bond Loan		491 358		491 358
Deferred tax	7	35 314	35 314	-
Total non-current liabilities		526 672		491 358
Current liabilities				
Bank overdraft facility		-		-
Accounts payable		20 359		20 359
Public duties payable		24 037		24 037
Short term liabilities, subsidiaries				
Other current liabilities		112 775		112 775
Total current liabilities		157 171		157 171
Total equity and liabilities		855 531		815 132

Review of preliminary Purchase Price Allocations - Cash Flow of 2021

CSAM Health Group, Consolidated	Note	(Reviewed)	Change	(Reported)
2022		2021		2021
Profit/(loss) before taxation		-89 110	-2 284	-86 826
Net financial items		47 289		47 289
Depreciation and amortisation	8	83 653	2 284	81 369
Cash earnings from operations		41 831		41 831
Changes in accounts receivables		-28 000		-28 000
Changes in accounts payables		8 883		8 883
Changes in other current receivables/liabilities		-5 692		-5 692
Changes in prepayment from customers		2 920		2 920
Changes in public duties payable		3 942		3 942
Taxes		-1 903		-1 903
Cash flow from operating activities		21 981		21 981
Capital Expenditure IP		-22 974		-22 974
Capital Expenditure other		-5 660		-5 660
Acquisitions		-197 456		-197 456
Cash flow from investing activities		-226 090		-226 090
Change in Debt		203 895		203 895
Net interest and financial fees		-23 547		-23 547
Cash flow from financing activities		180 348		180 348
Net change in cash and cash equivalents		-23 761		-23 761
Cash and cash equivalents at start of the period		304 616		304 616
Cash and cash equivalents at end of the period		280 855		280 855

Note 1 - Acquisitions of business and assets

2022

Name	Acquisition date	Percentage of voting equity instruments acquired	Consideration	1) Cost associated with the acquisition	Cost price
Carmona AB Health Analytics	February 28th 2022	100%	18 758	883	19 641
Total			18 758	883	19 641

Solutions to collect and sharing complete, timely and high-quality data. Unique specialist competence and close collaboration with renowned research and development-oriented businesses.

The cash outflow on acquisition are as follows

Cost price	19 641
Cash paid	(19 641)
Net cash acquired with the acquisitions	(480)
Net cash (outflow)/inflow	(20 122)

2021

Name	Acquisition date	Percentage of voting equity instruments acquired	Consideration	1) Cost associated with the acquisition	Cost price
Optima Corporation Ltd Public Safety	June 30th 2021	100%	25 780	1 712	27 492
Provides software and services for decision support and data visualisation, enabling more informed strategic and operational planning while supporting real-time critical analysis and decisions.					
MedSciNet AB Health Analytics	May 31st 2021	100%	31 269	1 378	32 647
Specialises in custom tailored solutions, design and development of web applications and online database systems for clinical trials and studies, quality registries and medical biobanks.					
Carmenta Public Safety AB Public Safety	February 15th 2021	100%	164 670	3 476	168 146
Provides complete software solutions for managing every aspect of emergency response. The company's core products include a comprehensive 112 and emergency response system, and emergency response software for emergency vehicles					
Total			221 719	6 566	228 285

The cash outflow on acquisition are as follows

Cost price 228 285

Cash paid (228 285)

Net cash acquired with the acquisitions 17 536

Net cash (outflow)/inflow (210 750)

1) Costs associated with the acquisition are recognised as part of the cost of shares or assets acquired

Note 1 - Continued

Carmona AB

On February 28th 2022 CSAM Health Group acquired Carmona AB, a specialist in providing unified patient data solutions to the life sciences sector, healthcare services and researchers. With this acquisition CSAM expanded its health analytics business, strategically laying the foundation for new and highly complementary solutions offering.

Optima Corporation Ltd

On June 30th 2021 CSAM Health Group acquired Optima Corporation Ltd expanding CSAMs product portfolio in the Public Safety domain and its customer base in countries such as New Zealand, Australia, the US, Canada, UK and others. With Optima's enhanced solutions for optimization of the rescue services through prediction and analytical software and services, CSAMs ambition is to be the preferred option for public safety and emergency response agencies who want advanced operational and planning capabilities that go beyond guesswork.

MedSciNet AB

On May 31st 2021 CSAM Health Group acquired MedSciNet AB entering Health Analytics as a new business area. Bringing the Swedish company and its broad customer portfolio into the CSAM family of eHealth solutions enables the Group to strengthen its total solutions offering to a broad and growing customer base of hospitals and other key healthcare providers, strengthens its presence in Europe and establishes a footprint in North America.

Carmenta Public Safety AB

On February 15th 2021 CSAM Health Group acquired Carmenta Public Safety AB. Carmenta Public Safety provides complete software solutions for managing every aspect of emergency response. With this acquisition CSAM expanded its Emergency & Acute offering across the Nordics and Europe, further strengthening its leading position in this key domain.

The aggregated fair value of identifiable assets and liabilities and the goodwill arising at the date of acquisition for material transactions are:

Consolidated 2022	Carmona AB	Total consolidated
Fair value of assets (before PPA)	(1 025)	(1 025)
Technology/IP	10 783	10 783
Contracts and customers relationship	7 544	7 544
Deferred Tax liability	(3 775)	(3 775)
Fair value of net assets	13 527	13 527
Goodwill arising on acquisition	6 114	6 114
Total acquisition cost	19 641	19 641
Net cash acquired with the subsidiary	(480)	(480)
Cash paid	(19 641)	(19 641)
Net cash outflow	(20 122)	(20 122)

Consolidated 2021	Optima Corporation Ltd	MedSciNet AB	Carmenta Public Safety AB	Total consolidated
Fair value of assets (before PPA)	19 917	3 295	15 022	38 234
Technology/IP	3 143	14 598	67 827	85 568
Contracts and customers relationship	10 370	10 258	93 445	114 073
Deferred Tax liability	(3 127)	(5 313)	(33 222)	(41 663)
Fair value of net assets	30 303	22 838	143 072	196 212
Goodwill arising on acquisition	-2 810	9 809	25 074	32 074
Total acquisition cost	27 492	32 647	168 146	228 285
Net cash acquired with the subsidiary	3 693	7 188	6 653	17 536
Cash paid	(27 492)	(32 647)	(168 146)	(228 285)
Net cash outflow	(23 798)	(25 459)	(161 493)	(210 750)

Note 2 - Operating Income

	CSAM Health Group AS		CSAM Health Group consolidated	
	2022	2021	2022	2021
Geographical distribution				
Norway	65 717	60 032	76 846	69 528
Sweden	9 675	9 662	169 379	158 173
Denmark	1 153	1 319	40 055	32 316
Finland	12	12	34 619	40 926
Rest of the world	13	18	47 258	28 501
Sum	76 570	71 044	368 158	329 444
Services to enterprises within the same group	115 669	55 942	-	-
Total sales revenue	192 239	126 986	368 158	329 444

Note 2 - Continued

Sales pr product group	CSAM Health Group AS		CSAM Health Group consolidated	
	2022	2021	2022	2021
Connected Healthcare	6 708	5 710	46 288	42 880
Women & Children's Health	26 305	24 100	44 832	40 400
LIMS	214	690	46 747	37 067
Public Safety	21 605	20 095	153 516	143 887
Medical Imaging	5 354	6 272	25 066	26 115
Medication Management	16 068	13 865	16 073	13 537
Health Analytics	-	-	26 640	10 013
Other	317	311	8 996	15 545
SUM	76 570	71 044	368 158	329 444
Services to enterprises within the same group	115 669	55 942	-	-
Total sales revenue	192 239	126 986	368 158	329 444

Note 3 - Payroll costs, number of employees, management remuneration and remuneration to the auditor

	CSAM Health Group AS		CSAM Health Group consolidated	
	2022	2021	2022	2021
Payroll expenses				
Wages	67 357	56 425	207 221	168 166
Capitalised payroll, intangible assets	-2 128	-5 352	-33 439	-22 974
Government grant ("SkatteFUNN-fundings")	-564	-2 109	-564	-2 109
Pension costs	1 141	878	18 962	14 799
External board member fees	2 103	1 331	2 103	1 351
Social security tax	9 780	7 570	35 679	28 935
Other payroll-related costs	1 251	562	3 887	2 598
Consulting personnel	3 286		17 737	
Total salary and personnel	82 226	59 307	251 584	190 766
Restructuring personnel expense	5 009	-	12 517	-
Total salary and personnel including restructuring expense	87 235	0	264 102	0
Average number of employees	62	52	317	269

Note 3 - Continued

	CSAM Health Group AS		CSAM Health Group consolidated	
Management remunerations	2022	2021	2022	2021
Remuneration to the chief executive officer:				
Wages	3 555	2 503	3 555	2 503
Variable compensation based on results	-	960	-	960
Pension costs	71	23	71	23
Other benefits	10	11	10	11
Board of Directors remuneration	2 022	2 021	2 022	2 021
Wages	1 870	1 000	1 870	1 000
Fees to auditor (amount net of VAT):	CSAM Health Group AS		CSAM Health Group consolidated	
	2022	2021	2022	2021
Statutory audit	568	1 761	1 988	2 738
Technical accounting and tax counselling	220	258	272	616
Other services	237	704	289	810
Total fees to the auditor	1 025	2 724	2 549	4 164

The chief executive officer is required to give six months' notice of resignation on either side. Beyond that, the company has no other obligations towards the chief executive officer as of 31.12.2022. There are no loans or guarantees to the group CEO, to members of the board or to executive personnel.

Note 4 - Other operating costs

Other operating costs are distributed as follows:	CSAM Health Group AS		CSAM Health Group consolidated	
	2022	2021	2022	2021
Rental costs	5 251	4 741	20 753	17 442
Data equipment, software etc.	6 779	3 505	11 244	7 422
Miscellaneous foreign services, legal services and audit	64 221	40 111	16 890	10 539
Office, seminars and telephone costs	3 143	1 696	6 079	4 138
Travel and car expenses	2 033	363	6 554	1 693
Advertising, marketing og exhibitions	1 617	1 244	2 523	2 927
Other	572	730	5 039	18 532
Capitalised other cost, intangible assets	(1 056)	-	-	-
Total other operating costs	82 562	52 390	69 084	62 691
Restructuring operating expense	179	-	783	-
Total other operating costs including restructuring expense	82 741	52 390	69 867	62 691

Note 5 - Intercompany balances and transactions

	CSAM Health AS		CSAM Public Safety AB	
	2022	2021	2022	2021
Inter Group Revenue				
Common services sold	80 518	29 542	-	-
Professional services sold	35 151	26 399	176	-
Interest income	30 083	21 921	24	-
Inter Group Expenses				
Common services purchased	-	-	37 139	9 645
License fee	15 046	13 972	-	-
Professional services purchased	42 756	21 211	7 269	3 312
Interest expenses	622	543	3 681	1 252
Assets and liabilities as per 31.12.				
Long term receivables	-	84 153	-	-
Short-term receivables	446 232	345 213	178	192
Impairment of receivables	(27 461)	(27 461)	-	-
Short-term liabilities	8 067	7 101	55 094	36 484

	CSAM Denmark A/S		CSAM Finland Oy	
Inter Group Revenue	2022	2021	2022	2021
Professional services sold	9 485	4 370	7 847	5 402
Interest income	-	-	163	117
Inter Group Expenses				
Common services purchased	5 044	728	6 537	4 853
Professional services purchased	295	-	3 408	1 945
Interest expenses	798	531	80	13
Assets and liabilities as per 31.12.				
Short-term receivables	-	1 370	2 690	1 404
Short-term liabilities	12 515	9 298	1 842	207

	CSAM Sweden AB		CSAM Karlstad AB	
	2022	2021	2022	2021
Inter Group Revenue				
License fee	-	-	15 046	13 972
Professional services sold	12 736	4 209	2 148	418
Interest income	495	527	262	316
Inter Group Expenses				
Common services purchased	14 972	10 919	1 508	2 426
Professional services purchased	18 656	15 974	11 922	12 398
Interest expenses	25 251	16 255	7	5 632
Assets and liabilities as per 31.12.				
Long term liabilities	-	-	-	84 153
Short-term receivables	8 742	7 060	2 723	3 730
Short-term liabilities	330 991	282 010	178	-

	CSAM Kibi Finland OY		CSAM Optima New Zealand Limited	
Inter Group Revenue	2022	2021	2022	2021
Professional services sold	3 109	2 389	11 933	5 633
Interest income	1 071	724	241	-
Inter Group Expenses				
Common services purchased	2 871	971	6 210	-
Professional services purchased	296	61	-	(391)
Interest expenses	174	58	1 418	144
Assets and liabilities as per 31.12.				
Short-term receivables	14 957	11 838	6 031	-
Short-term liabilities	3 251	1 219	23 838	8 386

	CSAM Optima UK Limited		CSAM Philippines Inc	
Inter Group Revenue	2022	2021	2022	2021
Professional services sold	-	-	14 289	9 191
Interest income	66	26	-	-
Inter Group Expenses				
Common services purchased	1 776	-	-	-
Professional services purchased	4 687	2 920	-	-
Interest expenses	320	-	-	-
Assets and liabilities as per 31.12.				
Short-term receivables	-	1 548	-	-
Short-term liabilities	7 712	-	48	48

	CSAM US Ltd		CSAM MedSciNet AB	
Inter Group Revenue	2022	2021	2022	2021
Interest income	511	-	16	-
Inter Group Expenses				
Common services purchased	123	-	40	-
Professional services purchased	7 584	2 948	3 501	-
Interest expenses	7	-	848	-
Assets and liabilities as per 31.12.				
Short-term receivables	9 750	-	389	-
Short-term liabilities	176	-	20 476	-

Inter Group Revenue	CSAM MedSciNet UK		CSAM Carmona AB	
	2022	2021	2022	2021
Interest income	83	-	24	-
Inter Group Expenses				
Common services purchased	1 606	-	2 691	-
Interest expenses		-	6	-
Assets and liabilities as per 31.12.				
Short-term receivables	-	-	4 042	-
Short-term liabilities	1 606	-	2 689	-

Inter Group Revenue	CSAM UK Ltd/CSAM Health Uk Ltd		CSAM Spain	
	2022	2021	2022	2021
Professional services sold	-	-	4 620	3 377
Interest income	462	346	462	9
Inter Group Expenses				
Interest expenses	165	355	126	-
Assets and liabilities as per 31.12.				
Short-term receivables	5 843	5 403	2 655	-
Short-term liabilities	33 000	32 822	2 822	-

	Foreign currency translation		Total	
Inter Group Revenue				
Common services sold	-	-	80 518	29 542
License fee	-	-	15 046	13 972
Professional services sold	(1 120)	(1 010)	100 374	60 379
Interest income	(462)	796	33 503	24 782
Inter Group Expenses				
Common services purchased	-	-	80 518	29 542
License fee	-	-	15 046	13 972
Professional services purchased	-	-	100 374	60 379
Interest expenses	-	-	33 503	24 782
Assets and liabilities as per 31.12.				
Long term receivables	-	-	-	84 153
Long term liabilities	-	-	-	84 153
Short-term receivables	-	-	504 232	377 760
Impairment of receivables	-	-	(27 461)	(27 461)
Short-term liabilities	(74)	185	504 232	377 760
Inter Group Interest Rate			2022	2021
Average 3 month Nibor			2,05%	0,47%
500 bps-margin on Bond Loan			5,00%	5,00%
150 bps-margin on inter group loans			1,50%	1,50%
Average inter group interest rate in CSAM Health Group			8,55%	6,97%

Note 6 - Bond Loan

Long-term liabilities	CSAM Health Group AS		CSAM Health Group consolidated	
	31/12/2022	31/12/2021	31/12/2022	31/12/2021
Bond Loan nominal value	500 000	500 000	500 000	500 000
Loan fees for amortisation	(5 574)	(8 642)	(5 574)	(8 642)
Bond Loan amortised cost	494 426	491 358	494 426	491 358
	2022	2021		
Average 3 month Nibor	2,05%	0,47%		
500 bps-margin	5,00%	5,00%		
Average interest rate	7,05%	5,47%		
Interest expenses	CSAM Health Group AS		CSAM Health Group consolidated	
	2022	2021	2022	2021
Other interest expenses	34 070	23 496	34 130	23 554
Amortisation of loan fees	3 068	3 143	3 068	3 143
Total other interest expenses	37 138	26 639	37 198	26 697
Other financial expenses	CSAM Health Group AS		CSAM Health Group consolidated	
	2022	2021	2022	2021
Foreign currency translation effects	(36)	180	8 782	19 106
Other financial expenses	1 247	(609)	1 870	1 498
Total other financial expenses	1 211	(429)	10 652	20 604

CSAM Health Group issued a bond loan in the end of September 2020. The bond is listed on Nordic ABM with the ticker code "CSAM01 PRO". Nordic ABM is a list of registered bonds for which Oslo Børs determines the rules of the list in consultation with market participants. Nordic ABM is not a regulated market nor Multilateral Trading Facility nor Organized Trading Facility, and is not subject to the provisions of the Securities Trading Act. The 20th April 2021 CSAM Health Group announced completion of a tap issue of MNOK 200. The outstanding amount under the bond is MNOK 500 as per 31.12.2022. The maturity date of the bond loan, including the tap issue, is 25 September 2024.

Mortgages and collaterals

CSAM Health Group AS has pledged its bank accounts, intercompany claims, material insurances, trade receivables, inventory, machinery and plant, each in an amount up to a total of MNOK 600 in favour of Nordic Trustee AS (as bond trustee on behalf of the bondholders) as security for its obligations under the "CSAM Health Group AS FRN senior secured NOK 500,000,000 bonds 2020/2024" bond loan with ISIN NO 0010893738.

The book value of account receivables in CSAM Health Group AS per 31.12.22 is MNOK 13.2 (2021: MNOK 15,3).

The book value of inventory in CSAM Health Group AS per 31.12.22 is 0 (2021: 0).

The book value of tangible fixed assets in CSAM Health Group AS per 31.12.22 is MNOK 4.3 (2021: MNOK 4,9).

CSAM Health Group AS has issued a guarantee and pledged its bank accounts, intercompany claims, material insurances, inventory, machinery and plant, each in an amount up to a total of MNOK 600, and all of the shares in CSAM Arcid AS, CSAM Prosang AB, CSAM Sweden AB and CSAM Finland Oy in favour of Nordic Trustee AS (as bond trustee on behalf of the bondholders) as security for the "CSAM Health Group AS FRN senior secured NOK 500,000,000 bonds 2020/2024" bond loan with ISIN NO 0010893738. Additionally, CSAM Health AS has pledged its trade receivables in favour of Nordea Bank Abp, filial in Norway in the amount of MNOK 40.

CSAM Karlstad AB has issued a guarantee and pledged its bank accounts, intercompany claims and material insurances in favour of Nordic Trustee AS (as bond trustee on behalf of the bondholders) as security for the "CSAM Health Group AS FRN senior secured NOK 500,000,000 bonds 2020/2024" bond loan with ISIN NO 0010893738.

CSAM Sweden AB has issued a guarantee and pledged its bank accounts, intercompany claims, material insurances, and business mortgages in favour of Nordic Trustee AS (as bond trustee on behalf of the bondholders) as security for the "CSAM Health Group AS FRN senior secured NOK 500,000,000 bonds 2020/2024" bond loan with ISIN NO 0010893738.

CSAM Finland Oy has issued a guarantee and pledged its bank accounts, intercompany claims, material insurances and enterprise mortgage certificates in favour of Nordic Trustee AS (as bond trustee on behalf of the bondholders) as security for the "CSAM Health Group AS FRN senior secured NOK 500,000,000 bonds 2020/2024" bond loan with ISIN NO 0010893738.

Note 7 - Tax

	CSAM Health Group AS	
	2022	2021
Payable tax		
Profit/loss before taxes	(2 315)	-5 759
Permanent differences	(1 935)	-6 521
Change in temporary differences	22 693	19 767
Utilisation of tax loss carried forward	(18 444)	-7 487
The year's tax base	-	-
Payable tax	-	-
Total tax payable	-	-

	CSAM Health Group AS		CSAM Health Group consolidated	
Temporary differences	31.12.2022	31.12.2021	31.12.2022	31.12.2021
Tangible fixed assets	4 868	9 674	23 912	(35 613)
Borrowing costs	6 107	11 176	6 107	11 176
Non-deductible interest	(10 920)	(11 681)	(10 920)	(11 681)
Deferred tax loss/profit	21 692	27 115	21 692	27 115
Unearned income (Skattefunn)	(4 966)	(4 942)	(4 966)	(4 942)
Accruals without tax effect	(7 372)	-	(11 533)	-
Tax losses carried forward	(143 338)	(161 020)	(296 425)	(294 244)
Temporary differences without tax effect	4 966	-	4 966	-
Total temporary differences	(128 962)	(129 679)	(266 987)	(308 189)
Calculated deferred tax/(deferred tax benefit)	(28 372)	(28 529)	(63 931)	(66 025)
Of which deferred tax asset that is not capitalised	-	-	33 900	24 826
Other tax effects	-	32	-	-
Deferred tax/(deferred tax benefit)	(28 372)	(28 497)	(30 031)	(41 199)
Explanation of this year's tax expense:				
Change in deferred tax	125	(14 604)	(5 155)	(4 522)
Change in deferred tax related to merger	-	-	-	-
Change in deferred tax related to transaction costs	-	15 568	-	-
Tax payable	-	-	422	1 974
This year's tax expense	125	964	(4 733)	(2 547)

Deferred tax benefit not capitalised

Entity	Country	Tax loss carried forward	Tax rate	Deferred tax benefit not capitalised
CSAM US Ltd	US	2 174	21%	-
Optima NZ Ltd	New Zealand	19 081	28%	2 059
CSAM Health UK	United Kingdom	9 310	19%	1 769
CSAM UK Ltd	United Kingdom	34 000	19%	6 460
CSAM Optima UK Ltd	United Kingdom	2 158	19%	410
CSAM Danmark AS	Denmark	23 777	22%	5 431
CSAM Sweden AB	Sweden	33 219	21%	6 843
CSAM Karlstad AB	Sweden	36 353	21%	7 489
CSAM Public Safety AB	Sweden	13 536	21%	2 788
CSAM Finland Oy	Finland	1 551	20%	310
CSAM Kibi Finland Oy	Finland	1 705	20%	341
Total		176 863		33 900

Distribution of Deferred Tax Asset and Deferred Tax on Tax jurisdictions

2022	CSAM Health Group consolidated	Tax jurisdiction				
		Norway	Philippines	New Zealand	USA	Sweden
Deferred Tax Asset		28 372	807	3 283	467	3 016
Deferred Tax		-	-	(2 898)	0	(29 422)
Deferred Tax Asset (net)	30 031	28 372	807	385	467	
Deferred Tax (net)	(26 406)					(26 406)

2021	CSAM Health Group consolidated	Tax jurisdiction				
		Norway	Philippines	New Zealand	USA	Sweden
Deferred Tax Asset	41 199	37 640	399	3 161	-	-
Deferred Tax	(35 314)	-	-	(2 990)		(32 323)

Note 8 - Intangible Assets

CSAM's software, developed and acquired, are amortised over five years from the approved delivery of a new product or new product version to the first customer. The amortisation period is assessed for the number of years the program version provides income by delivery of 1-2 upgrades of the product per year.

Goodwill is primarily related to the fact that one has acquired access to existing customer networks, partners and framework agreements that can be utilised to achieve increased sales for the entire group. The health sector is considered to be a market where growth is expected in the development of IT solutions/applications over a long period. Based on this, it is likely that one can utilize established positions to create results for several years to come. CSAM Health Group AS has thus paid, partially, for expected future earnings from the acquisitions of the eHealth products in the Swedish companies Databyrån AB and Mawell Sverige AB, as well as the Finnish companies Mawell Oy and the Mediware Oy, in addition to Amis AS, Natus and Clinsoft AS. This goodwill is considered to amortize over ten years, based on experience and sales in this sector having a long-term perspective. In 2018 CSAM Karlstad acquired an ambulance software solution of Saab AB. In 2019 Arcid AS and Kibi AB Group were acquired. In 2020 Fertsoft AB was acquired. In 2021 CSAM Public Safety AB, CSAM MedSciNet (Group) AB and CSAM New Zealand Ltd (Optima Group) were acquired. In 2022 CSAM Carmona AB was acquired.

CSAM Health Group AS	Software, acquired	Software, developed	Software, under development	Customer contracts	Goodwill	Web domain	Total
Acquisition cost at 01.01.22	24 458	153 458	15 547	4 997	87 571	-	286 030
Additions during the year	1 276	7	11 435	-	-	332	13 051
Divestments	-	-	(8 570)	-	-	-	(8 570)
Finalised development	-	7 996	(7 996)	-	-	-	-
Acquisition cost at 31.12.22	25 734	161 461	10 416	4 997	87 571	332	290 511
Accumulated amortisation as at 01.01.22	21 300	145 654	-	1 090	83 206	-	251 250
Amortisation charge for the year 2022	1 457	4 820	-	545	2 989	-	9 811
Impairment of intangible assets in 2022			3 891			-	3 891
Accumulated amortisation as at 31.12.22	22 757	150 474	3 891	1 635	86 196	-	264 953
Book value at 31.12.22	2 977	10 988	6 525	3 362	1 375	332	25 558
Amortisation charge for the year 2022	1 457	4 820	-	545	2 989	-	9 811
Impairment of intangible assets for the year 2022			3 891	-	-	-	3 891
Linear amortisation method; amortisation period:	5 years	5 years	No amortisation	10 years	5-10 years	No amortisation	

Due to changed assumptions for the development of an intangible asset, reducing the development scope and the commercial potential, an impairment of 3 891 NOK was recognised in 2022, bringing the booked value of the asset under development to nil as per 31 December 2022.

CSAM Health Group consolidated	Software, acquired	Software, developed	Software, under development	Customer contracts	Goodwill	Web domain	Total
Acquisition cost at 01.01.22	152 112	176 281	47 365	125 119	195 504		696 382
Updated PPAs	(11 067)	-	-	23 324	28 142	-	40 399
Capex development of products	-	-	35 777	-	-	-	35 777
Additions from acquired companies	10 876	-	-	7 607	6 164		24 647
Additions	1 276	-	-	-	-	332	1 608
Finalised development		24 400	(24 400)				
Currency effect on opening balance	(982)	(1 053)	(573)	(489)	(1 606)		(4 704)
Acquisition cost at 31.12.22	152 216	199 629	58 168	155 560	228 204	332	794 108
Accumulated amortisation as at 31.12.22	77 002	154 032	3 891	36 183	150 989	-	422 096
Book value at 31.12.22	75 214	45 597	54 277	119 377	77 216	332	372 012
Amortisation charge for the year 2022	28 704	23 696	-	11 580	21 096	-	85 076
Impairment of intangible assets in 2022	-	-	3 891	-	-		3 891
Linear amortisation method; amortisation period:	5 years	5 years	No amortisation	10 years	5-10 years	No amortisation	

Due to changed assumptions for the development of an intangible asset, reducing the development scope and the commercial potential, an impairment of 3 891 NOK was recognised in 2022, bringing the booked value of the asset under development to null as per 31 December 2022.

Note 9 - Tangible Fixed Assets

CSAM Health Group AS

Tangible fixed assets	Fixtures & fittings	Computer equipment	Total
Acquisition cost at 01.01.22	6 042	8 588	14 630
Additions during the year	314	1 199	1 513
Disposal of the year	-	-	-
Acquisition cost at 31.12.22	6 356	9 787	16 143
Accumulated depreciation as at 01.01.2022	2 993	6 728	9 721
Depreciation charge for the year 2022	945	1 149	2 093
Accumulated depreciation as at 31.12.22	3 938	7 877	11 814
Booked value as at 31.12.22	2 418	1 910	4 328
Depreciation charge for the year 2022	945	1 149	2 093
Linear depreciation method; depreciation period:	5 years	3 years	

CSAM Health Group consolidated

Tangible fixed assets	Fixtures & fittings	Computer equipment	Total
Acquisition cost at 01.01.22	7 931	12 981	20 912
Additions during the year	2 441	2 357	4 799
Disposal of the year	-	-	-
Acquisition cost at 31.12.22	10 372	15 338	25 711
Accumulated depreciation as at 31.12.22	5 685	10 888	16 573
Booked value as at 31.12.22	4 687	4 450	9 138
Depreciation charge for the year 2022	1 446	2 344	3 790
Linear depreciation method; depreciation period:	5 years	3 years	

Note 10 - Subsidiaries

Investments made by the parent company in the subsidiaries are accounted for using the cost method.

CASM Health Group AS owns shares in the following companies:

Subsidiaries (directly owned by Parent)	Acquisition	Business office	Owner's share	Voting rights
Aygo AS	November 2022	Oslo, Norway	100%	100%
CSAM (UK) Ltd	November 2008	Warwickshire, England	100%	100%
CSAM Sweden AB	January 2016	Solna, Sweden	100%	100%
CSAM Finland OY	January 2016	Oulo, Finland	100%	100%
CSAM Denmark A/S	May 2019	Herlev, Denmark	100%	100%
CSAM Spain SL	February 2021	Valencia, Spain	100%	100%
Subsidiaries (indirectly owned by Parent)	Acquisition	Business office	Owner's share	Voting rights
CSAM Health UK Ltd	November 2008	Warwickshire, England	100%	100%
CSAM Kibi Finland Oy	May 2019	Vantaa, Finland	100%	100%
CSAM Karlstad AB	May 2018	Karlstad, Sweden	100%	100%
CSAM Public Safety AB	February 2021	Göteborg, Sweden	100%	100%
CSAM MedSciNet AB	May 2021	Solna, Sweden	100%	100%
CSAM MedSciNet UK Ltd	May 2021	Reading, England	100%	100%
CSAM Optima (NZ) Ltd	June 2021	Auckland, New Zealand	100%	100%
CSAM Optima UK Ltd	June 2021	Reading, England	100%	100%
CSAM US Inc	June 2021	Oak Brook, US	100%	100%
CSAM Australia Pty Ltd	June 2021	Brisbane, Australia	100%	100%
CSAM Carmona AB	February 2022	Halmstad, Sweden	100%	100%
CSAM Philippines	June 2005	Cebu, Philippines	99,995 %	99,995 %

Entities consolidated in 2022	Book value as of 31.12.2022	Equity as of 31.12.2022	Company's result 2022
Aygo AS	2 864	2 864	-
CSAM (UK) Ltd	104	(27 925)	(78)
CSAM Sweden AB	209 249	57 656	(72 283)
CSAM Finland OY	30 356	20 864	(1 638)
CSAM Danmark A/S	1 369	(17 357)	(5 097)
CSAM Spain SL		457	1
CSAM Health UK Ltd		3 212	102
CSAM Kibi Finland Oy		9 315	(1 785)
CSAM Karlstad AB		50 879	(20 162)
CSAM Public Safety AB		726	(17 232)
CSAM MedSciNet AB		10 271	(45)
CSAM MedSciNet UK Ltd		2 775	487
CSAM Optima (NZ) Ltd		(1 891)	(6 577)
CSAM Optima UK Ltd		2 228	(2 080)
CSAM US Inc		10 331	1 357
CSAM Australia Pty Ltd		-	-
CSAM Carmona AB		3 980	(481)
CSAM Philippines		397	201

Note 11 - Accounts receivables

	CSAM Health Group AS		CSAM Health Group consolidated	
	31.12.2022	31.12.2021	31.12.2022	31.12.2021
Accounts receivables	13 219	15 348	51 292	81 514
Bad debt accrual	-	-	(141)	-
Total accounts receivables	13 219	15 348	51 151	81 514

Note 12 - Other receivables

	CSAM Health Group AS		CSAM Health Group consolidated	
	31.12.2022	31.12.2021	31.12.2022	31.12.2021
Earned, not invoiced revenue	283	690	13 456	8 139
Earned, not received Government Grants (SkatteFUNN)	2 087	3 538	2 087	3 538
Prepayments to suppliers	4 461	3 890	18 275	16 475
Other receivables	-	-	502	3 488
Total other receivables	6 831	8 117	34 319	31 639

Note 13 - Cash and cash equivalents

CSAM Health Group AS has an overdraft facility of MNOK 40 with Nordea Bank Norge AS. As per 31 December 2022 no amount of this facility was used.

Restricted cash:	CSAM Health Group AS		CSAM Health Group consolidated	
	31.12.2022	31.12.2021	31.12.2022	31.12.2021
Tax withholding	3 814	3 410	3 814	3 410
Deposits	-	-	947	2 615
Total restricted cash	3 814	3 410	4 762	6 025

Note 14 - Share capital and shareholder information

CSAM Health Group AS

The share capital consists of (in NOK 1000):	Number of ordinary shares	Per value	Capitalised value
Ordinary shares	20 967 404	0,1	2 097
Total	20 967 404	0,1	2 097

The company has the following shareholders:	Number of ordinary shares	Owner's share	Voting rights
EQUILIBRIUM AS	4 085 539	19,5%	19,5%
The Bank of New York Mellon SA/NV	1 556 033	7,4%	7,4%
The Northern Trust Comp, London Br	1 042 603	5,0%	5,0%
Skandinaviska Enskilda Banken AB	998 753	4,8%	4,8%
Goldman Sachs International	985 237	4,7%	4,7%
Skandinaviska Enskilda Banken AB	891 428	4,3%	4,3%
Pershing LLC	848 803	4,0%	4,0%
RØDNINGEN CONSULTING AS	793 385	3,8%	3,8%
Skandinaviska Enskilda Banken AB	677 616	3,2%	3,2%
HSBC Bank Plc	634 510	3,0%	3,0%
Skandinaviska Enskilda Banken AB	600 000	2,9%	2,9%
JPMorgan Chase Bank, N.A., London	510 938	2,4%	2,4%
EXPLICATIO AS	490 122	2,3%	2,3%
TUNIUM AS	490 122	2,3%	2,3%
SINT AS	448 002	2,1%	2,1%
The Bank of New York Mellon	445 000	2,1%	2,1%
CLEARSTREAM BANKING S.A.	420 111	2,0%	2,0%
Citibank, N.A.	407 158	1,9%	1,9%
BNP Paribas	400 000	1,9%	1,9%
Morgan Stanley & Co. International	337 522	1,6%	1,6%
Other Shareholders	3 904 522	18,62%	18,62%
Total	20 967 404	100%	100%

Shares held by Board of Directors and Executive Management

	Title	Owner's share
Åse Aulie Michelet	Chair of the Board	0,055 %
Hans Erik Robbestad	Board member	1,092 %
Gunnar Bjørkavåg	Board member	0,027 %
Kjellrun Borgmo	Board member	0,017 %
Marianne Elisabeth Johnsen	Board member	-
Mats Larson	Board member	0,014%
Sverre Flatby (through Equilibrium AS)	Chief Executive Officer	9,743 %
Einar Bonnevie (through Equilibrium AS)	Chief Financial Officer	9,743 %

Note 15 - Equity

CSAM Health Group AS

	Share capital	Share premium	Other equity	Total
Equity at 01.01.2022	2 097	301 605	-0	303 702
Net profit/(loss) for the year	-	(2 440)	-	(2 440)
Equity at 31.12.2022	2 097	299 165	-0	301 262

CSAM Health Group consolidated

	Share capital	Share premium	Other equity	Total
Reported Equity at 01.01.2022	2 097	164 506	-	166 603
Update of Purchase Price Allocations*	-	5 085	-	5 085
Reviewed opening balance of 01.01.2022	2 097	169 591	-	171 688
Net profit/(loss) for the year	-	-	(131 598)	(131 598)
Adjustments **	-	-	(6 012)	(6 012)
Translation differences and other changes	-	-	(5 305)	(5 305)
Reclassification	-	(142 915)	142 915	-
Equity at 31.12.2022	2 097	26 676	-	28 773

* Update of Purchase Price Allocations

Increased value of Goodwill and Intangible assets	40 399
Increased value of Deferred tax	(35 314)
Total effect on equity as per 01.01.2022	5 085

Increased amortisation of Goodwill and Intangible assets	(2 284)
Reduced tax expense from change in deferred tax	4 845
Increased profit of Financial Year 2021	2 561

Increased profit of FY 2021	2 561
Update of cost price acquisitions	2 524
Total effect on equity as per 01.01.2022	5 085

** Adjustments

Historical correction of DTA	(4 361)
Historical correction of VAT	(1 394)
Other adjustments	(257)
Total effect on equity as per 31.12.2022	(6 012)

Note 16 - Other current liabilities

	CSAM Health Group AS		CSAM Health Group consolidated	
	31.12.2022	31.12.2021	31.12.2022	31.12.2021
Prepayments from customers	746	24 849	44 222	74 379
Holiday pay accruals	6 870	5 328	22 941	19 393
Retirement liabilities	-	-	8 370	6 052
Received, not earned government grants (Skattefunn)	4 966	4 942	4 966	4 942
Payroll accruals	23	760	1 952	2 312
Restructuring accrual (ref note 18)	5 188	-	13 301	-
Other accruals	4 815	1 753	2 163	5 697
Total	22 608	37 631	97 915	112 775

Research and development

The CSAM Health Group has been involved in three projects approved by the Research Council of Norway for "SkatteFUNN" government grants in 2022. Please refer to Accounting principles for a description of the accounting treatment of such government grants. The table below show the amounts recognised in the income statement and the balance sheet statement for the current and prior financial year.

Government Grants (SkatteFUNN)	CSAM Health Group AS		CSAM Health Group consolidated	
	2022	2021	2022	2021
Other Income	1 498	1 212	1 498	1 212
Reduced personnel expenses	564	2 109	564	2 109
Total effect in profit loss-statement	2 062	3 321	2 062	3 321
SkatteFUNN Grant-receivable as per 31.12	2 086	3 538	2 086	3 538
Deferred SkatteFUNN as per 31.12	(4 966)	(4 942)	(4 966)	(4 942)
Total in balance sheet statement	(2 880)	(1 404)	(2 880)	(1 404)

Rental and leasing agreements

The group company has following rental and leasing contracts of significance:

	Annual cost (NOK 1 000)	Contract expiry	Applies to entity
Office Building lease Norway	4 349	14/08/2024	CSAM Health Group AS
Office Building lease Philippines	1 010	31/12/2026	CSAM Philippines Inc
Office Building lease Finland	1 100	Ongoing	CSAM Finland OY
Office Building lease Sweden	4 160	31/10/2024	CSAM Sweden AB
Office Building lease Sweden	3 740	31/12/2028	CSAM Public Safety AB
Office Building lease Sweden	1 153	30/04/2026	CSAM Karlstad AB
Office Building lease Sweden	760	31/05/2024	CSAM Carmona AB
Office Building lease New Zealand	1 020	31/05/2025	CSAM Optima (NZ) Ltd
Office Building lease Denmark	456	Ongoing	CSAM Denmark A/S
Office Building lease UK	522	Ongoing	CSAM Optima UK Ltd

Note 17 - Financial market risk

The Group does not make use of financial instruments in connection with the management of financial risk but relies on natural hedging as the Group has income and cost in reasonable proportion in the same currencies.

Liquidity risk

The Group has high leverage and may incur additional indebtedness in the future, also in the form of vendor loans (related to acquisitions).

The Group may not be able to repay all or part of the indebtedness, or alternatively, refinance all or part of the indebtedness on commercially reasonable terms. Further, under the bond terms, the Group will only be allowed to make distributions if it complies with certain predefined leverage ratios. Increased debt levels may also restrict the Issuer's ability to borrow additional capital on a timely basis to fund acquisition opportunities as they arise.

Interest rate risk

Cash flows related to the company's loan obligations are affected by interest rate changes in NIBOR. Based on the book capital as of 31.12.2022, 1 percentage point change in these interest rates affects cost with about NOK 5 million before tax.

Foreign currency risk

Fluctuations in exchange rates entail both direct and indirect financial risks for the company. There are no agreements in place that reduce this risk as at 31.12.2022. The Group has income and cost in NOK, SEK, DKK, EUR, AUD, NZD, CAD, QAR, USD and GBP, which represents an indirect hedge against currency fluctuations. It is decided to leave the cost in PHP unhedged.

The amount of capital raised through the bond issues in 2020 and 2021 is 500 MNOK, and by this the currency risk related to financing was eliminated.

On consolidation, the following exchange rates are used:

Country	Currency	2022		Currency	2021	
		Average rate 2022	Closing rate 31.12.22		Average rate 2021	Closing rate 31.12.21
Sweden	SEK	0,9506	0,9453	SEK	1,0019	0,9745
Philippines	PHP	0,1758	0,1772	PHP	0,1743	0,1729
Great Britain	GBP	11,8234	11,8541	GBP	11,8179	11,8875
Europe	EUR	10,1456	10,5138	EUR	10,1633	9,9888
Denmark	DKK	1,3618	1,4138	DKK	1,3666	1,3432
New Zealand	NZD	6,0912	6,2590	NZD*	6,0732	6,0250
USA	USD	9,6137	9,8573	USD*	8,6953	8,8194

* Entities not consolidated on full year basis in 2021

Note 18 - Subsequent events

At the end of 2022, after five acquisitions in the preceding 24 months, CSAM identified that there were additional synergies to be realised by streamlining the operating model for the individual Business Areas, as well as Common Service functions. In Q1-23 the company completed the implementation of a group-wide cost-saving programme. The effect of the programme is a cost-saving of 60 MNOK annually, which will gradually improve CSAM's financial flexibility to continue its growth.

Most of the restructuring cost and accruals in 2022 are related to this cost saving programme.

ALTERNATIVE PERFORMANCE MEASURES (APMs)

CSAM Alternative Performance Measures in the financial statements that are not defined under NGAAP. The Company believes that these measures provide useful supplementary information to investors and the Company's management as they provide supplemental information by adjusting for items that, in our view, do not give an indication of the periodic operating results or cash flows of CSAM, or should be assessed in a different context than its classification according to its nature.

Financial APMs are intended to enhance comparability of the results and cash flows from period to period, and to better allow for evaluation of the Company's performance. Because not all companies calculate financial figures in the same way, these are not always comparable to measures used by other companies.

These alternative performance measures are not intended to and should not replace those by NGAAP.

CSAM APMs

EBITDA: Earnings Before Interest, Taxes, Depreciation and Amortisation.

EBITDA-margin: EBITDA in percent of total operating revenue

EBITA: Earnings Before Interest, Taxes and Amortisation.

EBIT: Earnings Before Interest and Taxes.

Adjusted EBITDA: Reported EBITDA adjusted for one-offs and other non-recurring items

Adjusted Persex: Other expenses related to personnel where one-offs or other non-recurring items are adjusted for.

Adjusted other costs: Other opex where one-offs or other non-recurring items are adjusted for. Recurring

Revenue: Revenue that is recurring in nature, typically running service & maintenance and SaaS income linked to use of CSAM Software.

CapEx: Capitalised Expenditure, software development not opexed but transferred to the Balance Sheet as intangible assets Financial Review

Organic Growth

CSAM started publishing numbers for organic growth as from the first quarter of 2022. We are applying the following principles when reporting on organic growth:

- It is measured in local currency. We measure our Business Areas the same way and have a policy of not hedging FX. For information purposes we will also state the growth measured in our reporting currency, NOK.
- We are not including Other income in the calculation. Such income is neither strategic (e.g., invoicing of freight cost) nor repeatable (like the sale of Swedish scanner business in Q1 2022).
- We exclude Hardware sales from the calculation. Such income is not a focus area for a software company like CSAM.
- Some of the acquired businesses do not have sufficient accounting details to be able to establish proforma numbers for the previous period to compare with. For this reason, we have excluded MedSciNet and Carmona from the calculations. For FY2022, sales from these companies, comprising ~7% of total sales, are therefore conservatively assumed to have 0% growth Y/Y. Numbers pertaining to these businesses will be included as soon as data quality allows for it.
- We continue to forecast organic growth to be 5-10% annually long term.

Income statement regrouped as quarterly reports

CSAM Health Group AS			NOK thousand	CSAM Health Group Consolidated		
Full-year	Full-year				Full-year	Full-year
2022	2021	Note		Note	2022	2021
4 504	1 307		License sales		12 327	10 553
66 419	62 839		Service and maintenance		281 266	249 637
121 305	62 683	2,5	Professional Services		64 157	52 450
-	-		Hardware		8 919	16 663
11	157		Other operating income		1 488	140
192 239	126 986	2,5	Total sales revenue	2	368 158	329 444
1 498	1 212	16	Government grants (Skattefunn)	16	1 498	1 212
193 737	128 198		Total operating revenue		369 656	330 656
3 354	3 424		Cost of Goods and Services		33 380	35 368
82 226	59 307	3	Salary and personnel	3	251 584	190 766
82 562	52 390	4,5	Other operating cost	4,5	69 084	62 691
5 188	-	3,4	Restructuring Cost	3,4	13 301	-
173 330	115 120		Sum Cost		367 348	288 825

CSAM Health Group AS		NOK thousand		CSAM Health Group Consolidated	
Full-year	Full-year			Full-year	Full-year
2022	2021	Note		2022	2021
20 408	13 077		EBITDA	2 307	41 831
11%	10%		EBITDA-%	1%	13%
2 093	1 096	9	Depreciation	3 790	2 325
18 315	11 981		EBITA	-1 482	39 506
9 811	12 913	8	Amortisation of goodwill and licenses	85 076	81 328
3 891		8	Impairment	3 891	
4 613	-932		EBIT	-90 449	-41 822
30 083	21 921	5	Interest income from enterprises within the same group	-	-
1 960		5	Other interest income	1 968	-
-622	-543	5	Interest cost to enterprises within the same group	-	-
-37 138	-26 639	6	Interest expenses	-37 198	-26 691
-1 211	429	6	Other net financials	-10 652	-20 598
-2 314	-5 759		Profit before tax	-136 332	-89 110
125	964	7	Taxes	-4 733	-2 547
-2 440	-6 723		Profit/(loss) for the year	-131 598	-86 563

Adjustments to reported EBITDA

CSAM Health Group Consolidated		
NOK thousand	2022	
	Adjusted PersEx and Other Cost	Adjusted EBITDA
Reported EBITDA		2 307
Reported PersEx	251 584	
Restructuring Cost PersEx		12 517
Other PersEx settlements agreed	2 290	
Non recurring EO consultancy	2 200	
Actuarial and other PersEx recalculation Cebu	1 373	
Board compensation accruals	825	
Sum Other PersEx adjustments		6 688
Adjusted Persex	244 896	
Reported Other Cost	69 084	
Restructuring Cost Other cost		783
Marketing & Comms non recurring	729	
Travel expenses restructuring related	350	
Recruiting costs	583	
Legal aid and advice	547	
Assistance accounting and reporting non recurring	280	
Accrual Cebu tax cost	118	
Sum Other OpEx adjustments		2 607
Adjusted Other Cost	66 476	
Adjusted EBITDA		24 903

Auditors Report



To the General Meeting of CSAM Health Group AS

Independent Auditor's Report

Opinion

We have audited the financial statements of CSAM Health Group AS, which comprise:

- the financial statements of the parent company CSAM Health Group AS (the Company), which comprise the balance sheet as at 31 December 2022, the income statement and cash flow statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and
- the consolidated financial statements of CSAM Health Group AS and its subsidiaries (the Group), which comprise the balance sheet as at 31 December 2022, the income statement and cash flow statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion

- the financial statements comply with applicable statutory requirements,
- the financial statements give a true and fair view of the financial position of the Company as at 31 December 2022, and its financial performance and its cash flows for the year then ended in accordance with Norwegian Accounting Act and accounting standards and practices generally accepted in Norway, and
- the consolidated financial statements give a true and fair view of the financial position of the Group as at 31 December 2022, and its financial performance and its cash flows for the year then ended in accordance with Norwegian Accounting Act and accounting standards and practices generally accepted in Norway.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company and the Group as required by relevant laws and regulations in Norway and the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Board of Directors and the Managing Director (management) are responsible for the information in the Board of Directors' report and the other information accompanying the financial statements. The other information comprises information in the annual report, but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the information in the Board of Directors' report nor the other information accompanying the financial statements.



In connection with our audit of the financial statements, our responsibility is to read the Board of Directors' report and the other information accompanying the financial statements. The purpose is to consider if there is material inconsistency between the Board of Directors' report and the other information accompanying the financial statements and the financial statements or our knowledge obtained in the audit, or whether the Board of Directors' report and the other information accompanying the financial statements otherwise appear to be materially misstated. We are required to report if there is a material misstatement in the Board of Directors' report or the other information accompanying the financial statements. We have nothing to report in this regard.

Based on our knowledge obtained in the audit, it is our opinion that the Board of Directors' report

- is consistent with the financial statements and
- contains the information required by applicable statutory requirements.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's and the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern. The financial statements use the going concern basis of accounting insofar as it is not likely that the enterprise will cease operations.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

For further description of Auditor's Responsibilities for the Audit of the Financial Statements reference is made to: <https://revisorforeningen.no/revisjonsberetninger>

Oslo, 17 April 2023
PricewaterhouseCoopers AS

A handwritten signature in blue ink, appearing to read 'Jone Bauge', is written over a light blue horizontal line.

Jone Bauge
State Authorised Public Accountant

